1
|
Moslemi C, Saekmose SG, Larsen R, Bay JT, Brodersen T, Didriksen M, Hjalgrim H, Banasik K, Nielsen KR, Bruun MT, Dowsett J, Dinh KM, Mikkelsen S, Mikkelsen C, Hansen TF, Ullum H, Erikstrup C, Brunak S, Krogfelt KA, Storry JR, Ostrowski SR, Olsson ML, Pedersen OB. Genetic prediction of 33 blood group phenotypes using an existing genotype dataset. Transfusion 2023; 63:2297-2310. [PMID: 37921035 DOI: 10.1111/trf.17575] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/16/2023] [Revised: 08/03/2023] [Accepted: 08/10/2023] [Indexed: 11/04/2023]
Abstract
BACKGROUND Accurate blood type data are essential for blood bank management, but due to costs, few of 43 blood group systems are routinely determined in Danish blood banks. However, a more comprehensive dataset of blood types is useful in scenarios such as rare blood type allocation. We aimed to investigate the viability and accuracy of predicting blood types by leveraging an existing dataset of imputed genotypes for two cohorts of approximately 90,000 each (Danish Blood Donor Study and Copenhagen Biobank) and present a more comprehensive overview of blood types for our Danish donor cohort. STUDY DESIGN AND METHODS Blood types were predicted from genome array data using known variant determinants. Prediction accuracy was confirmed by comparing with preexisting serological blood types. The Vel blood group was used to test the viability of using genetic prediction to narrow down the list of candidate donors with rare blood types. RESULTS Predicted phenotypes showed a high balanced accuracy >99.5% in most cases: A, B, C/c, Coa /Cob , Doa /Dob , E/e, Jka /Jkb , Kna /Knb , Kpa /Kpb , M/N, S/s, Sda , Se, and Yta /Ytb , while some performed slightly worse: Fya /Fyb , K/k, Lua /Lub , and Vel ~99%-98% and CW and P1 ~96%. Genetic prediction identified 70 potential Vel negatives in our cohort, 64 of whom were confirmed correct using polymerase chain reaction (negative predictive value: 91.5%). DISCUSSION High genetic prediction accuracy in most blood groups demonstrated the viability of generating blood types using preexisting genotype data at no cost and successfully narrowed the pool of potential individuals with the rare Vel-negative phenotype from 180,000 to 70.
Collapse
Affiliation(s)
- Camous Moslemi
- Department of Clinical Immunology, Zealand University Hospital, Køge, Denmark
- Department of Clinical Immunology, Aarhus University Hospital, Aarhus, Denmark
- Department of Science and Environment, Roskilde University, Roskilde, Denmark
| | - Susanne G Saekmose
- Department of Clinical Immunology, Zealand University Hospital, Køge, Denmark
| | - Rune Larsen
- Department of Clinical Immunology, Zealand University Hospital, Køge, Denmark
| | - Jakob T Bay
- Department of Clinical Immunology, Zealand University Hospital, Køge, Denmark
| | - Thorsten Brodersen
- Department of Clinical Immunology, Zealand University Hospital, Køge, Denmark
| | - Maria Didriksen
- Department of Clinical Immunology, Copenhagen University Hospital, Rigshopitalet, Copenhagen, Denmark
| | | | - Karina Banasik
- Novo Nordisk Foundation Center for Protein Research, University of Copenhagen, Copenhagen, Denmark
| | - Kaspar R Nielsen
- Department of Clinical Immunology, Aalborg University Hospital, Aalborg, Denmark
| | - Mie T Bruun
- Department of Clinical Immunology, Odense University Hospital, Odense, Denmark
| | - Joseph Dowsett
- Department of Clinical Immunology, Copenhagen University Hospital, Rigshopitalet, Copenhagen, Denmark
| | - Khoa M Dinh
- Department of Clinical Immunology, Aarhus University Hospital, Aarhus, Denmark
| | - Susan Mikkelsen
- Department of Clinical Immunology, Aarhus University Hospital, Aarhus, Denmark
| | - Christina Mikkelsen
- Department of Clinical Immunology, Copenhagen University Hospital, Rigshopitalet, Copenhagen, Denmark
- Novo Nordisk Foundation Center for Basic Metabolic Research, University of Copenhagen, Copenhagen, Denmark
| | - Thomas F Hansen
- Novo Nordisk Foundation Center for Protein Research, University of Copenhagen, Copenhagen, Denmark
- Department of Neurology, Dansk Hovedpine Center and Multiple Sclerosis Center, Rigshospitalet, Glostrup, Denmark
| | | | - Christian Erikstrup
- Department of Clinical Immunology, Aarhus University Hospital, Aarhus, Denmark
| | - Søren Brunak
- Novo Nordisk Foundation Center for Protein Research, University of Copenhagen, Copenhagen, Denmark
| | | | - Jill R Storry
- Department of Laboratory Medicine, Lund University, Lund, Sweden
- Department of Clinical Immunology and Transfusion Medicine, Office for Medical Services, Region Skåne, Sweden
| | - Sisse R Ostrowski
- Department of Clinical Immunology, Copenhagen University Hospital, Rigshopitalet, Copenhagen, Denmark
- Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
| | - Martin L Olsson
- Department of Laboratory Medicine, Lund University, Lund, Sweden
- Department of Clinical Immunology and Transfusion Medicine, Office for Medical Services, Region Skåne, Sweden
| | - Ole B Pedersen
- Department of Clinical Immunology, Zealand University Hospital, Køge, Denmark
- Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
| |
Collapse
|
2
|
Proteome expression profiling of red blood cells during the tumorigenesis of hepatocellular carcinoma. PLoS One 2022; 17:e0276904. [DOI: 10.1371/journal.pone.0276904] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/08/2022] [Accepted: 10/14/2022] [Indexed: 11/10/2022] Open
Abstract
The early diagnosis of hepatocellular carcinoma (HCC) has not been clinically elucidated, leading to an increased mortality rate in patients with HCC. HCC is a systemic disease related to disorders of blood homeostasis, and the association between red blood cells (RBCs) and HCC tumorigenesis remains elusive. We performed data-independent acquisition proteomic analyses of 72 clinical RBC samples, including HCC (n = 30), liver cirrhosis (LC, n = 17), and healthy controls (n = 25), and characterized the clinical relevance of RBCs and tumorigenesis in HCC. We observed dynamic changes in RBCs during HCC tumorigenesis, and our findings indicate that, based on the protein expression profiles of RBCs, LC is a developmental stage closely approaching HCC. The expression of hemoglobin (HbA and HbF) in peripheral blood dynamically changed during HCC tumorigenesis, suggesting that immature erythroid cells exist in peripheral blood of HCC patients and that erythropoiesis is influenced by the onset of LC. We also identified the disrupted autophagy pathway in RBCs at the onset of LC, which persisted during HCC tumorigenesis. The oxytocin and GnRH pathways were disrupted and first identified during the development of LC into HCC. Significantly differentially expressed SMIM1, ANXA7, HBA1, and HBE1 during tumorigenesis were verified as promising biomarkers for the early diagnosis of HCC using parallel reaction monitoring technology. This study may enhance the understanding of HCC tumorigenesis from a different point of view and aid the early diagnosis of HCC.
Collapse
|
3
|
Identification of SMIM1 and SEZ6L2 as Potential Biomarkers for Genes Associated with Intervertebral Disc Degeneration in Pyroptosis. DISEASE MARKERS 2022; 2022:9515571. [PMID: 35578687 PMCID: PMC9107366 DOI: 10.1155/2022/9515571] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 03/19/2022] [Revised: 04/15/2022] [Accepted: 04/18/2022] [Indexed: 11/17/2022]
Abstract
Background. Inflammatory reactions and pyroptosis play an important role in the pathology of intervertebral disc degeneration (IDD). The aim of the present study was to investigate pyroptosis in the nucleus pulposus cells (NPCs) of inflammatory induced IDD by bioinformatic methods and to search for possible diagnostic biomarkers. Methods. Gene expression profiles related to IDD were downloaded from the GEO database to identify differentially expressed genes (DEGs) between inflammation-induced IDD and non-inflammatory intervention samples. Pyroptosis genes were then searched for, and their expression in IDD was analyzed. Weighted gene co-expression network analysis (WGCNA) was then used to search for modules of IDD genes associated with pyroptosis and intersected with DEGs to discover candidate genes that would be diagnostically valuable. A LASSO model was developed to screen for genes that met the requirements, and ROC curves were created to clarify the diagnostic value of the genetic markers. Ultimately, the screened genes were further validated, and their diagnostic value assessed by selecting gene sets from the GEO database. RT-PCR was used to assess the mRNA expression of diagnostic markers in the nucleus pulposus (NP). Pan-cancer analysis was applied to demonstrate the expression and prognostic value of the screened genes in various tumors. Results. A total of 733 DEGs were identified in GSE41883 and GSE27494, which were mainly enriched in transmembrane receptor protein serine/threonine, kinase signaling pathway, response to lipopolysaccharide, and other biological processes, and they were mainly related to TGF beta signaling pathway, toll-like receptor signaling pathway, and TNF signaling pathway. A total of 81 genes related to pyroptosis were identified in the literature, and eight genes related to IDD were identified in the Veen diagram, namely, IL1A, IL1B, NOD2, GBP1, IL6, AK1, EEF2K, and PYCARD. Eleven candidate genes were obtained after locating the intersection of pyroptosis-related module genes and DEGs according to WGCNA analysis. A total of six valid genes were obtained after constructing a machine learning model, and five key genes were finally identified after correlation analysis. GSE23132 and GSE56081 validated the candidate genes, and the final IDD-related diagnostic markers were obtained as SMIM1 and SEZ6L2. RT-PCR results indicated that the mRNA expression of both was significantly elevated in IDD. The pan-cancer analysis demonstrated that SMIM1 and SEZ6L2 have important roles in the expression and prognosis of various tumors. Conclusion. In conclusion, this research identifies SMIM1 and SEZ6L2 as important biomarkers of IDD associated with pyroptosis, which will help to unravel the development and pathogenesis of IDD and determine potential therapeutic targets.
Collapse
|
4
|
Using Whole Genome Sequencing to Characterize Clinically Significant Blood Groups Among Healthy Older Australians. Blood Adv 2022; 6:4593-4604. [PMID: 35420653 PMCID: PMC9636324 DOI: 10.1182/bloodadvances.2022007505] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/11/2022] [Accepted: 03/29/2022] [Indexed: 12/02/2022] Open
Abstract
There have been no comprehensive studies of a full range of blood group polymorphisms within the Australian population. This problem is compounded by the absence of any databases carrying genomic information on chronically transfused patients and low frequency blood group antigens in Australia. Here, we use RBCeq, a web server–based blood group genotyping software, to identify unique blood group variants among Australians and compare the variation detected vs global data. Whole-genome sequencing data were analyzed for 2796 healthy older Australians from the Medical Genome Reference Bank and compared with data from 1000 Genomes phase 3 (1KGP3) databases comprising 661 African, 347 American, 503 European, 504 East Asian, and 489 South Asian participants. There were 661 rare variants detected in this Australian sample population, including 9 variants that had clinical associations. Notably, we identified 80 variants that were computationally predicted to be novel and deleterious. No clinically significant rare or novel variants were found associated with the genetically complex ABO blood group system. For the Rh blood group system, 2 novel and 15 rare variants were found. Our detailed blood group profiling results provide a starting point for the creation of an Australian blood group variant database.
Collapse
|
5
|
Jadhao S, Davison CL, Roulis EV, Schoeman EM, Divate M, Haring M, Williams C, Shankar AJ, Lee S, Pecheniuk NM, Irving DO, Hyland CA, Flower RL, Nagaraj SH. RBCeq: A robust and scalable algorithm for accurate genetic blood typing. EBioMedicine 2022; 76:103759. [PMID: 35033986 PMCID: PMC8763639 DOI: 10.1016/j.ebiom.2021.103759] [Citation(s) in RCA: 6] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/07/2021] [Revised: 11/19/2021] [Accepted: 12/01/2021] [Indexed: 12/20/2022] Open
Abstract
Background While blood transfusion is an essential cornerstone of hematological care, patients requiring repetitive transfusion remain at persistent risk of alloimmunization due to the diversity of human blood group polymorphisms. Despite the promise, user friendly methods to accurately identify blood types from next-generation sequencing data are currently lacking. To address this unmet need, we have developed RBCeq, a novel genetic blood typing algorithm to accurately identify 36 blood group systems. Methods RBCeq can predict complex blood groups such as RH, and ABO that require identification of small indels and copy number variants. RBCeq also reports clinically significant, rare, and novel variants with potential clinical relevance that may lead to the identification of novel blood group alleles. Findings The RBCeq algorithm demonstrated 99·07% concordance when validated on 402 samples which included 29 antigens with serology and 9 antigens with SNP-array validation in 14 blood group systems and 59 antigens validation on manual predicted phenotype from variant call files. We have also developed a user-friendly web server that generates detailed blood typing reports with advanced visualization (https://www.rbceq.org/). Interpretation RBCeq will assist blood banks and immunohematology laboratories by overcoming existing methodological limitations like scalability, reproducibility, and accuracy when genotyping and phenotyping in multi-ethnic populations. This Amazon Web Services (AWS) cloud based platform has the potential to reduce pre-transfusion testing time and to increase sample processing throughput, ultimately improving quality of patient care. Funding This work was supported in part by Advance Queensland Research Fellowship, MRFF Genomics Health Futures Mission (76,757), and the Australian Red Cross LifeBlood. The Australian governments fund the Australian Red Cross Lifeblood for the provision of blood, blood products and services to the Australian community.
Collapse
Affiliation(s)
- Sudhir Jadhao
- Centre for Genomics and Personalised Health, Queensland University of Technology, Brisbane, Queensland 4059, Australia
| | - Candice L Davison
- Australian Red Cross Lifeblood Research and Development, Brisbane, Queensland, Australia
| | - Eileen V Roulis
- Australian Red Cross Lifeblood Research and Development, Brisbane, Queensland, Australia; Faculty of Health, Queensland University of Technology, Brisbane, Australia
| | - Elizna M Schoeman
- Australian Red Cross Lifeblood Research and Development, Brisbane, Queensland, Australia
| | - Mayur Divate
- Centre for Genomics and Personalised Health, Queensland University of Technology, Brisbane, Queensland 4059, Australia
| | - Mitchel Haring
- Office of eResearch, Queensland University of Technology, Brisbane, Queensland 4059, Australia
| | - Chris Williams
- Office of eResearch, Queensland University of Technology, Brisbane, Queensland 4059, Australia
| | - Arvind Jaya Shankar
- Centre for Genomics and Personalised Health, Queensland University of Technology, Brisbane, Queensland 4059, Australia
| | - Simon Lee
- Centre for Genomics and Personalised Health, Queensland University of Technology, Brisbane, Queensland 4059, Australia
| | - Natalie M Pecheniuk
- School of Biomedical Sciences, Queensland University of Technology, Brisbane, Australia
| | - David O Irving
- Research and Development, Australian Red Cross Blood Service, Sydney, New South Wales, Australia
| | - Catherine A Hyland
- Australian Red Cross Lifeblood Research and Development, Brisbane, Queensland, Australia; Faculty of Health, Queensland University of Technology, Brisbane, Australia
| | - Robert L Flower
- Australian Red Cross Lifeblood Research and Development, Brisbane, Queensland, Australia; Faculty of Health, Queensland University of Technology, Brisbane, Australia
| | - Shivashankar H Nagaraj
- Centre for Genomics and Personalised Health, Queensland University of Technology, Brisbane, Queensland 4059, Australia; Translational Research Institute, Brisbane, Australia.
| |
Collapse
|
6
|
Barile M, Imaz-Rosshandler I, Inzani I, Ghazanfar S, Nichols J, Marioni JC, Guibentif C, Göttgens B. Coordinated changes in gene expression kinetics underlie both mouse and human erythroid maturation. Genome Biol 2021; 22:197. [PMID: 34225769 PMCID: PMC8258993 DOI: 10.1186/s13059-021-02414-y] [Citation(s) in RCA: 28] [Impact Index Per Article: 9.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/08/2021] [Accepted: 06/21/2021] [Indexed: 02/07/2023] Open
Abstract
BACKGROUND Single-cell technologies are transforming biomedical research, including the recent demonstration that unspliced pre-mRNA present in single-cell RNA-Seq permits prediction of future expression states. Here we apply this RNA velocity concept to an extended timecourse dataset covering mouse gastrulation and early organogenesis. RESULTS Intriguingly, RNA velocity correctly identifies epiblast cells as the starting point, but several trajectory predictions at later stages are inconsistent with both real-time ordering and existing knowledge. The most striking discrepancy concerns red blood cell maturation, with velocity-inferred trajectories opposing the true differentiation path. Investigating the underlying causes reveals a group of genes with a coordinated step-change in transcription, thus violating the assumptions behind current velocity analysis suites, which do not accommodate time-dependent changes in expression dynamics. Using scRNA-Seq analysis of chimeric mouse embryos lacking the major erythroid regulator Gata1, we show that genes with the step-changes in expression dynamics during erythroid differentiation fail to be upregulated in the mutant cells, thus underscoring the coordination of modulating transcription rate along a differentiation trajectory. In addition to the expected block in erythroid maturation, the Gata1-chimera dataset reveals induction of PU.1 and expansion of megakaryocyte progenitors. Finally, we show that erythropoiesis in human fetal liver is similarly characterized by a coordinated step-change in gene expression. CONCLUSIONS By identifying a limitation of the current velocity framework coupled with in vivo analysis of mutant cells, we reveal a coordinated step-change in gene expression kinetics during erythropoiesis, with likely implications for many other differentiation processes.
Collapse
Affiliation(s)
- Melania Barile
- Department of Haematology, University of Cambridge, Cambridge, CB2 0AW UK
- Wellcome-Medical Research Council Cambridge Stem Cell Institute, University of Cambridge, Cambridge, CB2 0AW UK
| | - Ivan Imaz-Rosshandler
- Department of Haematology, University of Cambridge, Cambridge, CB2 0AW UK
- Wellcome-Medical Research Council Cambridge Stem Cell Institute, University of Cambridge, Cambridge, CB2 0AW UK
| | - Isabella Inzani
- University of Cambridge Metabolic Research Laboratories and MRC Metabolic Diseases Unit, Cambridge, CB2 0QQ UK
| | - Shila Ghazanfar
- Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, CB2 0RE UK
| | - Jennifer Nichols
- Wellcome-Medical Research Council Cambridge Stem Cell Institute, University of Cambridge, Cambridge, CB2 0AW UK
- Department of Physiology, Development and Neuroscience, University of Cambridge, Cambridge, CB2 3DY UK
| | - John C. Marioni
- Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, CB2 0RE UK
- Wellcome Sanger Institute, Wellcome Genome Campus, Cambridge, CB10 1SA UK
- European Molecular Biology Laboratory, European Bioinformatics Institute (EMBL-EBI), Wellcome Genome Campus, Cambridge, CB10 1SD UK
| | - Carolina Guibentif
- Department of Haematology, University of Cambridge, Cambridge, CB2 0AW UK
- Wellcome-Medical Research Council Cambridge Stem Cell Institute, University of Cambridge, Cambridge, CB2 0AW UK
- Sahlgrenska Center for Cancer Research, Department of Microbiology and Immunology, University of Gothenburg, 413 90 Gothenburg, Sweden
| | - Berthold Göttgens
- Department of Haematology, University of Cambridge, Cambridge, CB2 0AW UK
- Wellcome-Medical Research Council Cambridge Stem Cell Institute, University of Cambridge, Cambridge, CB2 0AW UK
| |
Collapse
|
7
|
SMIM1, carrier of the Vel blood group, is a tail-anchored transmembrane protein and readily forms homodimers in a cell-free system. Biosci Rep 2021; 40:222673. [PMID: 32301496 PMCID: PMC7953501 DOI: 10.1042/bsr20200318] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/05/2020] [Revised: 03/17/2020] [Accepted: 03/24/2020] [Indexed: 01/05/2023] Open
Abstract
Antibodies to the Vel blood group antigen can cause adverse hemolytic reactions unless Vel-negative blood units are transfused. Since the genetic background of Vel-negativity was discovered in 2013, DNA-based typing of the 17-bp deletion causing the phenotype has facilitated identification of Vel-negative blood donors. SMIM1, the gene underlying Vel, encodes a 78-amino acid erythroid transmembrane protein of unknown function. The transmembrane orientation of SMIM1 has been debated since experimental data supported both the N- and C-termini being extracellular. Likewise, computational predictions of its orientation were divided and potential alternatives such as monotopic or dual-topology have been discussed but not investigated. We used a cell-free system to explore the topology of SMIM1 when synthesized in the endoplasmic reticulum (ER). SMIM1 was tagged with an opsin-derived N-glycosylation reporter at either the N- or C-terminus and synthesized in vitro using rabbit reticulocyte lysate supplemented with canine pancreatic microsomes as a source of ER membrane. SMIM1 topology was then determined by assessing the N-glycosylation of its N- or C-terminal tags. Complementary experiments were carried out by expressing the same SMIM1 variants in HEK293T/17 cells and establishing their membrane orientation by immunoblotting and flow cytometry. Our data consistently indicate that SMIM1 has its short C-terminus located extracellularly and that it most likely belongs to the tail-anchored class of membrane proteins with the bulk of the polypeptide located in the cytoplasm. Having established its membrane orientation in an independent model system, future work can now focus on functional aspects of SMIM1 as a potential regulator of erythropoiesis.
Collapse
|
8
|
van der Rijst MVE, Abay A, Aglialoro F, van der Schoot CE, van den Akker E. SMIM1 missense mutations exert their effect on wild type Vel expression late in erythroid differentiation. Transfusion 2020; 61:236-245. [PMID: 33128268 DOI: 10.1111/trf.16169] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/26/2020] [Revised: 09/25/2020] [Accepted: 09/25/2020] [Indexed: 01/02/2023]
Abstract
BACKGROUND Vel expression on erythrocytes is variable due to polymorphisms, complicating Vel typing. Weak Vel expression can be caused by mutations within SMIM1 in a heterozygous setting, suggesting a dominant negative effect of SMIM1 mutants on wild type (wt)SMIM1 expression. Here we report how SMIM1 expression is regulated during erythropoiesis, to understand its variable expression on erythrocytes. STUDY DESIGN AND METHODS Peripheral blood reticulocytes at different stages, cultured erythroid precursors and HEK293T cells were used to investigate expression and putative competition between wtSMIM1 and mutated SMIM1 VEL*01W.01, (c.152T>A (p.Met51Lys)), VEL*01W.02 (c.152T>G (p.Met51Arg)), and VEL*01W.03 (c.161T>C (p.Leu54Pro)). RESULTS Depending on the mutations in SMIM1 an effect on total and membrane expression of SMIM1 was observed in transfected HEK293T cells, but co-expression of wtSMIM1 and mutatedSMIM1 did not have an effect on wtSMIM1 membrane expression. During differentiation of donors expressing VEL*01W.01, VEL*01W.03, Vel-positive, Vel-negative (homozygote SMIM1*64_80del), and Vel-heterozygote SMIM1*64_80del primary human erythroblasts no overt defect was found in Vel expression dynamics or total SMIM1 expression levels when compared with wtSMIM1 erythroblasts. However, during enucleation, total Vel expression was significantly lower on reticulocytes of Vel-weak donors expressing heterozygote mutated SMIM1 compared to Vel-positive or Vel-heterozygote SMIM1*64_80del donors, while Vel expression on extruded nuclei was maintained. In addition, reticulocyte maturation in vivo showed further loss of Vel expression in these individuals and nearly absent on erythrocytes. CONCLUSION These results suggest that SMIM1 mutations exert a dominant negative effect on wtSMIM1 probably by affecting SMIM1 multimerization and thereby Vel epitope presentation at the latest stages of erythroid differentiation.
Collapse
Affiliation(s)
- Marea V E van der Rijst
- Department of Hematopoiesis, Sanquin Research and Landsteiner Laboratory, AUMC, Amsterdam, The Netherlands.,Department of Experimental Immunohematology, Sanquin Research and Landsteiner Laboratory, AUMC, Amsterdam, The Netherlands
| | - Asena Abay
- Department of Hematopoiesis, Sanquin Research and Landsteiner Laboratory, AUMC, Amsterdam, The Netherlands
| | - Francesca Aglialoro
- Department of Hematopoiesis, Sanquin Research and Landsteiner Laboratory, AUMC, Amsterdam, The Netherlands
| | - C Ellen van der Schoot
- Department of Experimental Immunohematology, Sanquin Research and Landsteiner Laboratory, AUMC, Amsterdam, The Netherlands
| | - Emile van den Akker
- Department of Hematopoiesis, Sanquin Research and Landsteiner Laboratory, AUMC, Amsterdam, The Netherlands
| |
Collapse
|
9
|
Lack of the multidrug transporter MRP4/ABCC4 defines the PEL-negative blood group and impairs platelet aggregation. Blood 2020; 135:441-448. [PMID: 31826245 DOI: 10.1182/blood.2019002320] [Citation(s) in RCA: 12] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/03/2019] [Accepted: 12/02/2019] [Indexed: 12/21/2022] Open
Abstract
The rare PEL-negative phenotype is one of the last blood groups with an unknown genetic basis. By combining whole-exome sequencing and comparative global proteomic investigations, we found a large deletion in the ABCC4/MRP4 gene encoding an ATP-binding cassette (ABC) transporter in PEL-negative individuals. The loss of PEL expression on ABCC4-CRISPR-Cas9 K562 cells and its overexpression in ABCC4-transfected cells provided evidence that ABCC4 is the gene underlying the PEL blood group antigen. Although ABCC4 is an important cyclic nucleotide exporter, red blood cells from ABCC4null/PEL-negative individuals exhibited a normal guanosine 3',5'-cyclic monophosphate level, suggesting a compensatory mechanism by other erythroid ABC transporters. Interestingly, PEL-negative individuals showed an impaired platelet aggregation, confirming a role for ABCC4 in platelet function. Finally, we showed that loss-of-function mutations in the ABCC4 gene, associated with leukemia outcome, altered the expression of the PEL antigen. In addition to ABCC4 genotyping, PEL phenotyping could open a new way toward drug dose adjustment for leukemia treatment.
Collapse
|
10
|
Thornton N, Karamatic Crew V, Tilley L, Green CA, Tay CL, Griffiths RE, Singleton BK, Spring F, Walser P, Alattar AG, Jones B, Laundy R, Storry JR, Möller M, Wall L, Charlewood R, Westhoff CM, Lomas-Francis C, Yahalom V, Feick U, Seltsam A, Mayer B, Olsson ML, Anstee DJ. Disruption of the tumour-associated EMP3 enhances erythroid proliferation and causes the MAM-negative phenotype. Nat Commun 2020; 11:3569. [PMID: 32678083 PMCID: PMC7366909 DOI: 10.1038/s41467-020-17060-4] [Citation(s) in RCA: 14] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/11/2018] [Accepted: 05/29/2020] [Indexed: 12/14/2022] Open
Abstract
The clinically important MAM blood group antigen is present on haematopoietic cells of all humans except rare MAM-negative individuals. Its molecular basis is unknown. By whole-exome sequencing we identify EMP3, encoding epithelial membrane protein 3 (EMP3), as a candidate gene, then demonstrate inactivating mutations in ten known MAM-negative individuals. We show that EMP3, a purported tumour suppressor in various solid tumours, is expressed in erythroid cells. Disruption of EMP3 by CRISPR/Cas9 gene editing in an immortalised human erythroid cell line (BEL-A2) abolishes MAM expression. We find EMP3 to associate with, and stabilise, CD44 in the plasma membrane. Furthermore, cultured erythroid progenitor cells from MAM-negative individuals show markedly increased proliferation and higher reticulocyte yields, suggesting an important regulatory role for EMP3 in erythropoiesis and control of cell production. Our data establish MAM as a new blood group system and demonstrate an interaction of EMP3 with the cell surface signalling molecule CD44.
Collapse
Affiliation(s)
- Nicole Thornton
- International Blood Group Reference Laboratory, NHS Blood and Transplant, Bristol, UK.
| | - Vanja Karamatic Crew
- International Blood Group Reference Laboratory, NHS Blood and Transplant, Bristol, UK
| | - Louise Tilley
- International Blood Group Reference Laboratory, NHS Blood and Transplant, Bristol, UK
| | - Carole A Green
- Bristol Institute for Transfusion Sciences, NHS Blood and Transplant and NIHR Blood and Transplant Unit in Red Cell Products, University of Bristol, Bristol, UK
| | - Chwen Ling Tay
- International Blood Group Reference Laboratory, NHS Blood and Transplant, Bristol, UK
| | - Rebecca E Griffiths
- Bristol Institute for Transfusion Sciences, NHS Blood and Transplant and NIHR Blood and Transplant Unit in Red Cell Products, University of Bristol, Bristol, UK
| | - Belinda K Singleton
- Bristol Institute for Transfusion Sciences, NHS Blood and Transplant and NIHR Blood and Transplant Unit in Red Cell Products, University of Bristol, Bristol, UK
| | - Frances Spring
- Bristol Institute for Transfusion Sciences, NHS Blood and Transplant and NIHR Blood and Transplant Unit in Red Cell Products, University of Bristol, Bristol, UK
| | - Piers Walser
- International Blood Group Reference Laboratory, NHS Blood and Transplant, Bristol, UK
| | - Abdul Ghani Alattar
- Division of Hematology and Transfusion Medicine, Department of Laboratory Medicine, Lund University, Lund, Sweden
| | - Benjamin Jones
- International Blood Group Reference Laboratory, NHS Blood and Transplant, Bristol, UK
| | - Rosalind Laundy
- International Blood Group Reference Laboratory, NHS Blood and Transplant, Bristol, UK
| | - Jill R Storry
- Division of Hematology and Transfusion Medicine, Department of Laboratory Medicine, Lund University, Lund, Sweden
- Department of Clinical Immunology and Transfusion Medicine, Office of Medical Services, Lund, Sweden
| | - Mattias Möller
- Division of Hematology and Transfusion Medicine, Department of Laboratory Medicine, Lund University, Lund, Sweden
| | - Lorna Wall
- Reference Laboratory, New Zealand Blood Service, Auckland, New Zealand
| | | | | | | | - Vered Yahalom
- Magen David Adom, National Blood Services, Ramat Gan, Israel
| | - Ute Feick
- Deutsches Rotes Kreuz, Blood Donor Service, Institute Bad Kreuznach, Bad Kreuznach, Germany
| | - Axel Seltsam
- German Red Cross Blood Service NSTOB, Institute Springe, Springe, Germany
| | - Beate Mayer
- Institute of Transfusion Medicine, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany
| | - Martin L Olsson
- Division of Hematology and Transfusion Medicine, Department of Laboratory Medicine, Lund University, Lund, Sweden
- Department of Clinical Immunology and Transfusion Medicine, Office of Medical Services, Lund, Sweden
| | - David J Anstee
- Bristol Institute for Transfusion Sciences, NHS Blood and Transplant and NIHR Blood and Transplant Unit in Red Cell Products, University of Bristol, Bristol, UK
| |
Collapse
|
11
|
Ito S, Kaito S, Miyazaki T, Kikuchi G, Isa K, Tsuneyama H, Kurita R, Ogasawara K, Uchikawa M, Satake M. A new antigen SUMI carried on glycophorin A encoded by the GYPA*M with c.91A>C (p.Thr31Pro) belongs to the MNS blood group system. Transfusion 2020; 60:1287-1293. [PMID: 32358867 DOI: 10.1111/trf.15828] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/27/2019] [Revised: 03/19/2020] [Accepted: 03/23/2020] [Indexed: 11/29/2022]
Abstract
BACKGROUND MNS is one of the highly polymorphic blood groups comprising many antigens generated by genomic recombination among the GYPA, GYPB, and GYPE genes as well as by single-nucleotide changes. We report a patient with red blood cell (RBC) antibody against an unknown low-frequency antigen, tentatively named SUMI, and investigated its carrier molecule and causal gene. STUDY DESIGN AND METHODS Standard serologic tests, including enzyme tests, were performed. Monoclonal anti-SUMI-producing cells (HIRO-305) were established by transformation and hybridization methods using lymphocytes from a donor having anti-SUMI. SUMI+ RBCs were examined by immunocomplex capture fluorescence analysis (ICFA) using HIRO-305 and murine monoclonal antibodies against RBC membrane proteins carrying blood group antigens. Genomic DNA was extracted from whole blood, and the GYPA gene was analyzed by polymerase chain reactions and Sanger sequencing. RESULTS Serologic screening revealed that 23 of the 541,522 individuals (0.0042%) were SUMI+, whereas 1351 of the 10,392 individuals (13.0%) had alloanti-SUMI. SUMI antigen was sensitive to ficin, trypsin, pronase, and neuraminidase, but resistant to α-chymotrypsin and sulfydryl-reducing agents. ICFA revealed that the SUMI antigen was carried on glycophorin A (GPA). According to Sanger sequencing and cloning, the SUMI+ individuals had a GYPA*M allele with c.91A>C (p.Thr31Pro), which may abolish the O-glycan attachment site. CONCLUSIONS The new low-frequency antigen SUMI is carried on GPA encoded by the GYPA*M allele with c.91A>C (p.Thr31Pro). Neuraminidase sensitivity suggests that glycophorin around Pro31 are involved in the SUMI determinant.
Collapse
Affiliation(s)
- Shoichi Ito
- Japanese Red Cross Tohoku Block Blood Center, Miyagi, Japan
| | - Sayaka Kaito
- Japanese Red Cross Kanto-Koshinetsu Block Blood Center, Tokyo, Japan
| | - Toru Miyazaki
- Japanese Red Cross Hokkaido Block Blood Center, Sapporo, Japan
| | - Go Kikuchi
- Japanese Red Cross Central Blood Institute, Tokyo, Japan
| | - Kazumi Isa
- Japanese Red Cross Central Blood Institute, Tokyo, Japan
| | - Hatsue Tsuneyama
- Japanese Red Cross Kanto-Koshinetsu Block Blood Center, Tokyo, Japan.,Japanese Red Cross Central Blood Institute, Tokyo, Japan
| | - Ryo Kurita
- Japanese Red Cross Central Blood Institute, Tokyo, Japan
| | | | - Makoto Uchikawa
- Japanese Red Cross Kanto-Koshinetsu Block Blood Center, Tokyo, Japan
| | | |
Collapse
|
12
|
Kelley LP, Nylander A, Arnaud L, Schmoker AM, St Clair RM, Gleason LA, Souza JM, Storry JR, Olsson ML, Ballif BA. Dimerization of small integral membrane protein 1 promotes cell surface presentation of the Vel blood group epitope. FEBS Lett 2020; 594:1261-1270. [PMID: 31879955 DOI: 10.1002/1873-3468.13726] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/27/2019] [Accepted: 12/03/2019] [Indexed: 01/04/2023]
Abstract
The Vel blood group antigen is carried on the short extracellular segment of the 78-amino-acid-long, type II transmembrane protein SMIM1 of unknown function. Here, using biochemical analysis and flow cytometry of cells expressing wild-type and mutant alleles of SMIM1, we demonstrate that dimerization of SMIM1 promotes cell surface display of the Vel epitope. We show that SMIM1 dimerization is mediated both by an extracellular Cys77-dependent, homomeric disulfide linkage and via a GxxxG helix-helix interaction motif in the transmembrane domain. These results provide important context for the observed variability in reactivity patterns of clinically important anti-Vel identified in patient sera.
Collapse
Affiliation(s)
- Liam P Kelley
- Department of Biology, University Vermont, Burlington, VT, USA
| | - Anja Nylander
- Division of Hematology and Transfusion Medicine, Department of Laboratory Medicine, Lund University, Lund, Sweden.,Department of Internal Medicine, Hässleholm-Kristianstad Hospitals, Kristianstad, Sweden
| | - Lionel Arnaud
- Department of Biology, University Vermont, Burlington, VT, USA
| | - Anna M Schmoker
- Department of Biology, University Vermont, Burlington, VT, USA
| | | | | | - Jessica M Souza
- Department of Biology, University Vermont, Burlington, VT, USA
| | - Jill R Storry
- Division of Hematology and Transfusion Medicine, Department of Laboratory Medicine, Lund University, Lund, Sweden.,Clinical Immunology and Transfusion Medicine, Office of Medical Services, Region Skåne, Lund, Sweden
| | - Martin L Olsson
- Division of Hematology and Transfusion Medicine, Department of Laboratory Medicine, Lund University, Lund, Sweden.,Clinical Immunology and Transfusion Medicine, Office of Medical Services, Region Skåne, Lund, Sweden
| | - Bryan A Ballif
- Department of Biology, University Vermont, Burlington, VT, USA
| |
Collapse
|
13
|
Fichou Y, Berlivet I, Richard G, Tournamille C, Castilho L, Férec C. Defining Blood Group Gene Reference Alleles by Long-Read Sequencing: Proof of Concept in the ACKR1 Gene Encoding the Duffy Antigens. Transfus Med Hemother 2019; 47:23-32. [PMID: 32110191 DOI: 10.1159/000504584] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/31/2019] [Accepted: 11/01/2019] [Indexed: 01/31/2023] Open
Abstract
Background In the novel era of blood group genomics, (re-)defining reference gene/allele sequences of blood group genes has become an important goal to achieve, both for diagnostic and research purposes. As novel potent sequencing technologies are available, we thought to investigate the variability encountered in the three most common alleles of ACKR1, the gene encoding the clinically relevant Duffy antigens, at the haplotype level by a long-read sequencing approach. Materials and Methods After long-range PCR amplification spanning the whole ACKR1 gene locus (∼2.5 kilobases), amplicons generated from 81 samples with known genotypes were sequenced in a single read by using the Pacific Biosciences (PacBio) single molecule, real-time (SMRT) sequencing technology. Results High-quality sequencing reads were obtained for the 162 alleles (accuracy >0.999). Twenty-two nucleotide variations reported in databases were identified, defining 19 haplotypes: four, eight, and seven haplotypes in 46 ACKR1*01, 63 ACKR1*02, and 53 ACKR1*02N.01 alleles, respectively. Discussion Overall, we have defined a subset of reference alleles by third-generation (long-read) sequencing. This technology, which provides a "longitudinal" overview of the loci of interest (several thousand base pairs) and is complementary to the second-generation (short-read) next-generation sequencing technology, is of critical interest for resolving novel, rare, and null alleles.
Collapse
Affiliation(s)
- Yann Fichou
- EFS, Inserm, Univ Brest, UMR 1078, GGB, Brest, France.,Laboratoire d'Excellence GR-Ex, Paris, France
| | | | | | - Christophe Tournamille
- Laboratoire d'Excellence GR-Ex, Paris, France.,IMRB-Inserm U955 Equipe 2 Transfusion et Maladies du Globule Rouge, EFS Ile-de-France, Créteil, France
| | | | - Claude Férec
- EFS, Inserm, Univ Brest, UMR 1078, GGB, Brest, France.,Laboratoire de Génétique Moléculaire et d'Histocompatibilité, CHU Morvan, Brest, France
| |
Collapse
|
14
|
Fürst D, Tsamadou C, Neuchel C, Schrezenmeier H, Mytilineos J, Weinstock C. Next-Generation Sequencing Technologies in Blood Group Typing. Transfus Med Hemother 2019; 47:4-13. [PMID: 32110189 DOI: 10.1159/000504765] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/01/2019] [Accepted: 11/07/2019] [Indexed: 12/14/2022] Open
Abstract
Sequencing of the human genome has led to the definition of the genes for most of the relevant blood group systems, and the polymorphisms responsible for most of the clinically relevant blood group antigens are characterized. Molecular blood group typing is used in situations where erythrocytes are not available or where serological testing was inconclusive or not possible due to the lack of antisera. Also, molecular testing may be more cost-effective in certain situations. Molecular typing approaches are mostly based on either PCR with specific primers, DNA hybridization, or DNA sequencing. Particularly the transition of sequencing techniques from Sanger-based sequencing to next-generation sequencing (NGS) technologies has led to exciting new possibilities in blood group genotyping. We describe briefly the currently available NGS platforms and their specifications, depict the genetic background of blood group polymorphisms, and discuss applications for NGS approaches in immunohematology. As an example, we delineate a protocol for large-scale donor blood group screening established and in use at our institution. Furthermore, we discuss technical challenges and limitations as well as the prospect for future developments, including long-read sequencing technologies.
Collapse
Affiliation(s)
- Daniel Fürst
- Institute for Clinical Transfusion Medicine and Immunogenetics Ulm, German Red Cross Blood Transfusion Service, Baden Wuerttemberg/Hessen, and University Hospital Ulm, Ulm, Germany.,Institute of Transfusion Medicine, University of Ulm, Ulm, Germany
| | - Chrysanthi Tsamadou
- Institute for Clinical Transfusion Medicine and Immunogenetics Ulm, German Red Cross Blood Transfusion Service, Baden Wuerttemberg/Hessen, and University Hospital Ulm, Ulm, Germany.,Institute of Transfusion Medicine, University of Ulm, Ulm, Germany
| | - Christine Neuchel
- Institute for Clinical Transfusion Medicine and Immunogenetics Ulm, German Red Cross Blood Transfusion Service, Baden Wuerttemberg/Hessen, and University Hospital Ulm, Ulm, Germany.,Institute of Transfusion Medicine, University of Ulm, Ulm, Germany
| | - Hubert Schrezenmeier
- Institute for Clinical Transfusion Medicine and Immunogenetics Ulm, German Red Cross Blood Transfusion Service, Baden Wuerttemberg/Hessen, and University Hospital Ulm, Ulm, Germany.,Institute of Transfusion Medicine, University of Ulm, Ulm, Germany
| | - Joannis Mytilineos
- Institute for Clinical Transfusion Medicine and Immunogenetics Ulm, German Red Cross Blood Transfusion Service, Baden Wuerttemberg/Hessen, and University Hospital Ulm, Ulm, Germany.,Institute of Transfusion Medicine, University of Ulm, Ulm, Germany
| | - Christof Weinstock
- Institute for Clinical Transfusion Medicine and Immunogenetics Ulm, German Red Cross Blood Transfusion Service, Baden Wuerttemberg/Hessen, and University Hospital Ulm, Ulm, Germany.,Institute of Transfusion Medicine, University of Ulm, Ulm, Germany
| |
Collapse
|
15
|
van der Rijst MVE, Voorn L, Veldhuisen B, Jongerius JM, van den Akker E, van der Schoot CE. Identification of a novel single-nucleotide mutation in SMIM1 gene that results in low Vel antigen expression. Transfusion 2019; 59:E8-E10. [PMID: 31218697 PMCID: PMC7079045 DOI: 10.1111/trf.15411] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/12/2019] [Revised: 05/20/2019] [Accepted: 05/29/2019] [Indexed: 11/28/2022]
Affiliation(s)
- Marea V E van der Rijst
- Department of Hematopoiesis, AUMC, Amsterdam, The Netherlands.,Department of Experimental Immunohematology, Sanquin Research and Landsteiner Laboratory, AUMC, Amsterdam, The Netherlands
| | - Lesley Voorn
- Department of Research and Lab Services, National Screening Laboratory Sanquin, Sanquin, Amsterdam, The Netherlands
| | - Barbera Veldhuisen
- Department of Immunohematology Diagnostic Services, Sanquin, Amsterdam, The Netherlands
| | - John M Jongerius
- Department of Research and Lab Services, National Screening Laboratory Sanquin, Sanquin, Amsterdam, The Netherlands
| | | | - C Ellen van der Schoot
- Department of Experimental Immunohematology, Sanquin Research and Landsteiner Laboratory, AUMC, Amsterdam, The Netherlands
| |
Collapse
|
16
|
Aniweh Y, Nyarko PB, Quansah E, Thiam LG, Awandare GA. SMIM1 at a glance; discovery, genetic basis, recent progress and perspectives. Parasite Epidemiol Control 2019; 5:e00101. [PMID: 30906890 PMCID: PMC6416411 DOI: 10.1016/j.parepi.2019.e00101] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/05/2018] [Revised: 12/28/2018] [Accepted: 03/06/2019] [Indexed: 11/18/2022] Open
Abstract
Recent elucidation of the genetic basis of the Vel blood group system has offered the field of blood transfusion medicine an additional consideration in determining the causes of hemolytic reactions after a patient is transfused. The identification of the SMIM1 gene to be responsible for the Vel blood group allows molecular based tools to be developed to further dissect the function of this antigen. Genetic signatures such as the homozygous 17 bp deletion and the heterozygous 17 bp deletion in combination with other single nucleotide polymorphisms (SNPs) and insertion sequences regulate the expression level of the gene. With this knowledge, it is now possible to study this antigen in-depth.
Collapse
Affiliation(s)
- Yaw Aniweh
- West Africa Centre for Cell Biology of Infectious Pathogens, University of Ghana, Accra, Ghana
| | - Prince B. Nyarko
- West Africa Centre for Cell Biology of Infectious Pathogens, University of Ghana, Accra, Ghana
- Department of Biochemistry, Cell and Molecular Biology, College of Basic and Applied Sciences, University of Ghana, Accra, Ghana
| | - Evelyn Quansah
- West Africa Centre for Cell Biology of Infectious Pathogens, University of Ghana, Accra, Ghana
- Department of Biochemistry, Cell and Molecular Biology, College of Basic and Applied Sciences, University of Ghana, Accra, Ghana
| | - Laty Gaye Thiam
- West Africa Centre for Cell Biology of Infectious Pathogens, University of Ghana, Accra, Ghana
- Department of Biochemistry, Cell and Molecular Biology, College of Basic and Applied Sciences, University of Ghana, Accra, Ghana
| | - Gordon A. Awandare
- West Africa Centre for Cell Biology of Infectious Pathogens, University of Ghana, Accra, Ghana
- Department of Biochemistry, Cell and Molecular Biology, College of Basic and Applied Sciences, University of Ghana, Accra, Ghana
| |
Collapse
|
17
|
Omae Y, Ito S, Takeuchi M, Isa K, Ogasawara K, Kawabata K, Oda A, Kaito S, Tsuneyama H, Uchikawa M, Wada I, Ohto H, Tokunaga K. Integrative genome analysis identified the KANNO blood group antigen as prion protein. Transfusion 2019; 59:2429-2435. [DOI: 10.1111/trf.15319] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/03/2018] [Revised: 03/25/2019] [Accepted: 03/30/2019] [Indexed: 12/30/2022]
Affiliation(s)
- Yosuke Omae
- Department of Human Genetics, Graduate School of MedicineThe University of Tokyo Tokyo Japan
| | - Shoichi Ito
- Department of Laboratory TestingJapanese Red Cross Tohoku Block Blood Center Miyagi Japan
| | - Mayumi Takeuchi
- Department of Cell Science, Institute of Biomedical SciencesFukushima Medical University Fukushima Japan
| | - Kazumi Isa
- Department of Research and DevelopmentJapanese Red Cross Central Blood Institute Tokyo Japan
| | - Kenichi Ogasawara
- Department of Research and DevelopmentJapanese Red Cross Central Blood Institute Tokyo Japan
| | - Kinuyo Kawabata
- Department of Blood Transfusion and Transplantation ImmunologyFukushima Medical University Hospital Fukushima Japan
| | - Akira Oda
- Blood Group SectionJapanese Red Cross Kanto‐Koshinetsu Block Blood Center Tokyo Japan
| | - Sayaka Kaito
- Blood Group SectionJapanese Red Cross Kanto‐Koshinetsu Block Blood Center Tokyo Japan
| | - Hatsue Tsuneyama
- Blood Group SectionJapanese Red Cross Kanto‐Koshinetsu Block Blood Center Tokyo Japan
| | - Makoto Uchikawa
- Blood Group SectionJapanese Red Cross Kanto‐Koshinetsu Block Blood Center Tokyo Japan
| | - Ikuo Wada
- Department of Cell Science, Institute of Biomedical SciencesFukushima Medical University Fukushima Japan
| | - Hitoshi Ohto
- Department of Blood Transfusion and Transplantation ImmunologyFukushima Medical University Hospital Fukushima Japan
| | - Katsushi Tokunaga
- Department of Human Genetics, Graduate School of MedicineThe University of Tokyo Tokyo Japan
| |
Collapse
|
18
|
Dezan MR, Costa-Neto A, Gomes CN, Ribeiro IH, Oliveira VB, Conrado MCAV, Oliveira TGM, Carvalho MLP, Aranha AF, Bosi SRA, Salles NA, Krieger JE, Pereira AC, Sabino EC, Rocha V, Mendrone-Junior A, Dinardo CL, Levi JE. SMIM1 intron 2 gene variations leading to variability in Vel antigen expression among Brazilian blood donors. Blood Cells Mol Dis 2019; 77:23-28. [PMID: 30939337 DOI: 10.1016/j.bcmd.2019.03.006] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/11/2019] [Revised: 03/22/2019] [Accepted: 03/23/2019] [Indexed: 10/27/2022]
Abstract
BACKGROUND There is a significant inter-individual heterogeneity of Vel antigen expression which can lead to inaccuracies on Vel phenotyping of blood donors and, potentially, to hemolytic post-transfusion reactions. Our aim was to evaluate the impact of genetic variants in the SMIM1 intron 2 on the expression of Vel antigen among Brazilian blood donors harboring the c.64_80del17 deletion in heterozygosity. METHODS Donors presenting the SMIM1 c.64_80del17 in heterozygosity were included in the study and subjected to SMIM1 intron 2 direct sequencing aiming to genotype the following polymorphisms: rs143702418, rs1181893, rs191041962, rs6673829, rs1175550 and rs9424296. RESULTS SMIM1 intron 2 sequencing was performed on two hundred donors presenting one c.64_80del17 allele. The rs1175550 polymorphism significantly impacted on Vel antigen expression. Variations in the strength of agglutination on Vel phenotyping were also observed according to the rs6673829 genotype, but this difference did not persist with statistical relevance after multivariate analysis. CONCLUSION The presence of the rs1175550A allele of SMIM1 is significantly and independently associated with a decrease in Vel antigen expression. Even though the population in Brazil is intensely mixed, the allele frequencies obtained in the current study were very similar to that reported for Europeans.
Collapse
Affiliation(s)
- Marcia Regina Dezan
- Fundação Pro-Sangue Hemocentro de Sao Paulo, Sao Paulo, Brazil; Instituto de Medicina Tropical, Universidade de Sao Paulo, Sao Paulo, Brazil.
| | - Abel Costa-Neto
- Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Disciplina de Hematologia, Universidade de Sao Paulo, Sao Paulo, Brazil
| | | | | | | | | | - Théo Gremen M Oliveira
- Fundação Pro-Sangue Hemocentro de Sao Paulo, Sao Paulo, Brazil; Laboratory of Genetics and Molecular Cardiology, Heart Institute (InCor), University of Sao Paulo School of Medicine, Brazil
| | - Mariana L P Carvalho
- Laboratory of Genetics and Molecular Cardiology, Heart Institute (InCor), University of Sao Paulo School of Medicine, Brazil
| | - Aline Fernanda Aranha
- Laboratory of Genetics and Molecular Cardiology, Heart Institute (InCor), University of Sao Paulo School of Medicine, Brazil
| | - Silvia R A Bosi
- Fundação Pro-Sangue Hemocentro de Sao Paulo, Sao Paulo, Brazil
| | - Nanci A Salles
- Fundação Pro-Sangue Hemocentro de Sao Paulo, Sao Paulo, Brazil
| | - José Eduardo Krieger
- Laboratory of Genetics and Molecular Cardiology, Heart Institute (InCor), University of Sao Paulo School of Medicine, Brazil
| | - Alexandre Costa Pereira
- Laboratory of Genetics and Molecular Cardiology, Heart Institute (InCor), University of Sao Paulo School of Medicine, Brazil
| | | | - Vanderson Rocha
- Fundação Pro-Sangue Hemocentro de Sao Paulo, Sao Paulo, Brazil; Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Disciplina de Hematologia, Universidade de Sao Paulo, Sao Paulo, Brazil; Churchill Hospital, NHSBT, Oxford University, Oxford, UK
| | | | - Carla Luana Dinardo
- Fundação Pro-Sangue Hemocentro de Sao Paulo, Sao Paulo, Brazil; Instituto de Medicina Tropical, Universidade de Sao Paulo, Sao Paulo, Brazil.
| | - José Eduardo Levi
- Instituto de Medicina Tropical, Universidade de Sao Paulo, Sao Paulo, Brazil
| |
Collapse
|
19
|
Yu Y, Wang Z, Zhu L, Lin Y, Chang H, Xu H. The Polymorphism of SMIM1 Gene in Chinese Dividuals. Indian J Hematol Blood Transfus 2019; 35:137-143. [PMID: 30828161 DOI: 10.1007/s12288-018-0963-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/08/2017] [Accepted: 05/05/2018] [Indexed: 11/24/2022] Open
Abstract
The SMIM1 gene, which encodes the high-frequency blood group antigen Vel, has not been systematically analyzed at the molecular level in Chinese individuals. To better understand the SMIM1 genetic polymorphism, we assessed mutations among healthy Chinese individuals, patients with red blood cell autoantibodies and hematological disease. A total of 130 patients with hematological disease (case I group), 50 patients with red blood cell autoantibodies (case II group), and 500 healthy controls (control group) were enrolled. Exons 3 and 4 in the SMIM1 gene were sequenced to identify genetic variants or mutations. A polyclonal anti-Vel antibody was used to evaluate the expression of the Vel antigenon red blood cells in patients with novel alleles. The novel alleles of the SMIM1 gene were intron 3 position 193 (TT, CT, CC), 194 (GG, AG), 3' untranslated region positions 81 (CC, CA) and 87 (AA, CA). The single nucleotide polymorphism (SNP) frequencies of intron 3 position 193 TT, CT, CC were 13.1, 39.2, 47.7% in case group I, 6.7, 33.3, 60.0% in case group II and 8.5, 35.6, 56.2% in the control group, respectively. Other minor allele frequencies were all greater than 10% and all SNPs in Chinese showed Vel antigen expression on RBC membranes. The allele at intron 3 position 193 was the most frequent mutant allele found in the Chinese population and Vel antigen deficiency may not cause problems in Chinese patients with hematological diseases and RBC autoantibodies.
Collapse
Affiliation(s)
- Ying Yu
- 1Institute of Laboratory Medicine, Jiangsu Key Laboratory of Medicine, Jiangsu University, Zhenjiang, China
- Department of Laboratory Medicine, Chinese Medicine Hospital of Zhejiang, Hangzhou, China
| | - Zhejiong Wang
- Department of Laboratory Medicine, Chinese Medicine Hospital of Zhejiang, Hangzhou, China
| | - Linchao Zhu
- Department of Laboratory Medicine, Chinese Medicine Hospital of Zhejiang, Hangzhou, China
| | - Yushiang Lin
- 3Department of Clinical Medicine, Peking University Health Science Center, Beijing, China
- 4College of Medicine, Aerospace Center Hospital, Beijing, China
| | - Haochun Chang
- 3Department of Clinical Medicine, Peking University Health Science Center, Beijing, China
- 4College of Medicine, Aerospace Center Hospital, Beijing, China
| | - Huaxi Xu
- 1Institute of Laboratory Medicine, Jiangsu Key Laboratory of Medicine, Jiangsu University, Zhenjiang, China
| |
Collapse
|
20
|
Hyland CA, Roulis EV, Schoeman EM. Developments beyond blood group serology in the genomics era. Br J Haematol 2019; 184:897-911. [PMID: 30706459 DOI: 10.1111/bjh.15747] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/22/2023]
Abstract
Blood group serology and single nucleotide polymorphism-based genotyping platforms are accurate but do not provide a comprehensive cover for all 36 blood group systems and do not cover the antigen diversity observed among population groups. This review examines the extent to which genomics is shaping blood group serology. Resources for genomics include the Human Reference Genome Sequence assembly; curated blood group tables listing variants; public databases providing information on genetic variants from world-wide studies; and massively parallel sequencing technologies. Blood group genomic studies span the spectrum, from bioinformatic data mining of huge data sets containing whole genome and whole exome information to laboratory investigations utilising targeted sequencing approaches. Blood group predictions based on genome sequencing and genomic studies are proving accurate, and have shown utility in both research and reference settings. Overall, studies confirm the potential for blood group genomics to reshape donor and patient transfusion management strategies to provide more compatible blood transfusions.
Collapse
Affiliation(s)
- Catherine A Hyland
- Clinical Services and Research, Australian Red Cross Blood Service, Kelvin Grove, Queensland, Australia
| | - Eileen V Roulis
- Clinical Services and Research, Australian Red Cross Blood Service, Kelvin Grove, Queensland, Australia
| | - Elizna M Schoeman
- Clinical Services and Research, Australian Red Cross Blood Service, Kelvin Grove, Queensland, Australia
| |
Collapse
|
21
|
van der Rijst MVE, Lissenberg-Thunnissen SN, Ligthart PC, Visser R, Jongerius JM, Voorn L, Veldhuisen B, Vidarsson G, van den Akker E, van der Schoot CE. Development of a recombinant anti-Vel immunoglobulin M to identify Vel-negative donors. Transfusion 2019; 59:1359-1366. [PMID: 30702752 DOI: 10.1111/trf.15147] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/20/2018] [Revised: 11/28/2018] [Accepted: 12/03/2018] [Indexed: 01/10/2023]
Abstract
BACKGROUND Alloimmunization against the high-frequency Vel blood group antigen may result in transfusion reactions or hemolytic disease of fetus and newborn. Patients with anti-Vel alloantibodies require Vel-negative blood but Vel-negative individuals are rare (1:4000). Identification of Vel-negative donors ensures availability of Vel-negative blood; however, accurate Vel blood group typing is difficult due to variable Vel antigen expression and limited availability of anti-Vel typing sera. We report the production of a recombinant anti-Vel that also identifies weak Vel expression. STUDY DESIGN AND METHODS A recombinant anti-Vel monoclonal antibody was produced by cloning the variable regions from an anti-Vel-specific B cell isolated from an alloimmunized patient into a vector harboring the constant regions of immunoglobulin (Ig)G1-kappa or IgM-kappa. Antibody Vel specificity was tested by reactivity to SMIM1-transfected HEK293T cells and by testing various red blood cells (RBCs) of donors with normal, weak, or no Vel expression. High-throughput donor screening applicability was tested using an automated blood group analyzer. RESULTS A Vel-specific IgM class antibody was produced. The antibody was able to distinguish between Vel-negative and very weak Vel antigen-expressing RBCs by direct agglutination and in high-throughput settings using a fully automated blood group analyzer and performed better than currently used human anti-Vel sera. High-throughput screening of 13,288 blood donations identified three new Vel-negative donors. CONCLUSION We generated a directly agglutinating recombinant anti-Vel IgM, M3F5S-IgM, functional in manual, automated agglutination assays and flow cytometry settings. This IgM anti-Vel will improve diagnostics by facilitating the identification of Vel-negative blood donors.
Collapse
Affiliation(s)
- Marea V E van der Rijst
- Department of Hematopoiesis, Sanquin Research and Landsteiner Laboratory, AUMC, Amsterdam, The Netherlands.,Department of Experimental Immunohematology, Sanquin Research and Landsteiner Laboratory, AUMC, Amsterdam, The Netherlands
| | | | - Peter C Ligthart
- Department of Immunohematology Diagnostic Services, Sanquin, Amsterdam, The Netherlands
| | - Remco Visser
- Department of Experimental Immunohematology, Sanquin Research and Landsteiner Laboratory, AUMC, Amsterdam, The Netherlands
| | - John M Jongerius
- Department of Research and Lab Services, National Screening Laboratory Sanquin, Sanquin, Amsterdam, the Netherlands
| | - Lesley Voorn
- Department of Research and Lab Services, National Screening Laboratory Sanquin, Sanquin, Amsterdam, the Netherlands
| | - Barbera Veldhuisen
- Department of Immunohematology Diagnostic Services, Sanquin, Amsterdam, The Netherlands
| | - Gestur Vidarsson
- Department of Experimental Immunohematology, Sanquin Research and Landsteiner Laboratory, AUMC, Amsterdam, The Netherlands
| | - Emile van den Akker
- Department of Hematopoiesis, Sanquin Research and Landsteiner Laboratory, AUMC, Amsterdam, The Netherlands
| | - C Ellen van der Schoot
- Department of Experimental Immunohematology, Sanquin Research and Landsteiner Laboratory, AUMC, Amsterdam, The Netherlands
| |
Collapse
|
22
|
Dezan MR, Dinardo CL, Rocha V, Mendrone-Junior A, Levi JE. Prevalence of SMIM1 c.64_80del17 homozygotes in southeastern Brazil: the Vel-negative phenotype. Transfusion 2019; 59:428. [PMID: 30615815 DOI: 10.1111/trf.15059] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/12/2018] [Revised: 08/30/2018] [Accepted: 09/06/2018] [Indexed: 12/01/2022]
Affiliation(s)
- Marcia R Dezan
- Immunohematology, Fundação Pró-Sangue Hemocentro de São Paulo, São Paulo, Brazil.,Institute of Tropical Medicine, Universidade de São Paulo, São Paulo, Brazil
| | - Carla L Dinardo
- Immunohematology, Fundação Pró-Sangue Hemocentro de São Paulo, São Paulo, Brazil.,Institute of Tropical Medicine, Universidade de São Paulo, São Paulo, Brazil
| | - Vanderson Rocha
- Immunohematology, Fundação Pró-Sangue Hemocentro de São Paulo, São Paulo, Brazil.,Discipline of Hematology, University of São Paulo School of Medicine, São Paulo, Brazil.,Churchill Hospital, NHSBT, Oxford University, Oxford, UK
| | | | - Jose E Levi
- Institute of Tropical Medicine, Universidade de São Paulo, São Paulo, Brazil
| |
Collapse
|
23
|
Schoeman EM, Roulis EV, Perry MA, Flower RL, Hyland CA. Comprehensive blood group antigen profile predictions for Western Desert Indigenous Australians from whole exome sequence data. Transfusion 2018; 59:768-778. [PMID: 30520525 DOI: 10.1111/trf.15047] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/17/2018] [Revised: 09/17/2018] [Accepted: 09/26/2018] [Indexed: 12/25/2022]
Abstract
BACKGROUND The distribution of RBC antigens, which define blood group types, differs among populations. In contrast to many world populations, blood group profiles for Indigenous Australians have not been well studied. As it is now possible to predict comprehensive blood group antigen profiles from genomic data sets, we aimed to apply this for Indigenous Australians and to provide a comparison to other major world populations. STUDY DESIGN AND METHODS Whole exome sequence data for 72 Western Desert Indigenous Australians was provided by the Telethon Kids Institute. Variants (against hg19) were annotated using computer software (ANNOVAR, Qiagen Bioinformatics) and filtered to include only variants in genes for 36 blood group systems, and the transcription factors KLF1 and GATA1. The RHCE*C allele and RHD zygosity were identified by copy number variant analysis of sequence alignments. The impact of missense variants was investigated in silico using a meta-predictor of disease-causing variants (Meta-SNP). RESULTS For 21 blood group systems the predicted blood group antigen frequencies were comparable to those for other major world populations. For 13 systems, interesting points of contrast were identified. Furthermore, we identified 12 novel variants, one novel D allele, and four rare variants with potential clinical significance. CONCLUSION This is the first systematic assessment of genomic data to elucidate blood group antigen profiles for Indigenous Australians who are linguistically and culturally diverse. Our study paves the way to understanding the geographic distribution of blood group variants in different Indigenous groups and the associated RBC phenotypes. This in turn is expected to guide transfusion practice for Indigenous individuals.
Collapse
Affiliation(s)
- Elizna M Schoeman
- Clinical Services and Research, Australian Red Cross Blood Service, Kelvin Grove, Queensland, Australia
| | - Eileen V Roulis
- Clinical Services and Research, Australian Red Cross Blood Service, Kelvin Grove, Queensland, Australia
| | - Maree A Perry
- Clinical Services and Research, Australian Red Cross Blood Service, Kelvin Grove, Queensland, Australia
| | - Robert L Flower
- Clinical Services and Research, Australian Red Cross Blood Service, Kelvin Grove, Queensland, Australia
| | - Catherine A Hyland
- Clinical Services and Research, Australian Red Cross Blood Service, Kelvin Grove, Queensland, Australia
| |
Collapse
|
24
|
Gassner C, Degenhardt F, Meyer S, Vollmert C, Trost N, Neuenschwander K, Merki Y, Portmann C, Sigurdardottir S, Zorbas A, Engström C, Gottschalk J, Amar El Dusouqui S, Waldvogel-Abramovski S, Rigal E, Tissot JD, Tinguely C, Mauvais SM, Sarraj A, Bessero D, Stalder M, Infanti L, Buser A, Sigle J, Weingand T, Castelli D, Braisch MC, Thierbach J, Heer S, Schulzki T, Krawczak M, Franke A, Frey BM. Low-Frequency Blood Group Antigens in Switzerland. Transfus Med Hemother 2018; 45:239-250. [PMID: 30283273 DOI: 10.1159/000490714] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/26/2018] [Accepted: 06/04/2018] [Indexed: 12/12/2022] Open
Abstract
Background High-frequency blood group antigens (HFA) are present in >90% of the human population, according to some reports even in >99% of individuals. Therefore, patients lacking HFA may become challenging for transfusion support because compatible blood is hardly found, and if the patient carries alloantibodies, the cross-match will be positive with virtual every red cell unit tested. Methods In this study, we applied high-throughput blood group SNP genotyping on >37,000 Swiss blood donors, intending to identify homozygous carriers of low-frequency blood group antigens (LFA). Results 326 such individuals were identified and made available to transfusion specialists for future support of patients in need of rare blood products. Conclusion Thorough comparison of minor allele frequencies using population genetics revealed heterogeneity of allele distributions among Swiss blood donors which may be explained by the topographical and cultural peculiarities of Switzerland. Moreover, geographically localized donor subpopulations are described which contain above-average numbers of individuals carrying rare blood group genotypes.
Collapse
Affiliation(s)
- Christoph Gassner
- Blood Transfusion Service Zürich, Swiss Red Cross (SRC), Department of Molecular Diagnostics & Research (MOC), Schlieren, Switzerland
| | - Frauke Degenhardt
- Institute of Clinical Molecular Biology, Christian-Albrechts-University of Kiel, Kiel, Germany
| | - Stefan Meyer
- Blood Transfusion Service Zürich, Swiss Red Cross (SRC), Department of Molecular Diagnostics & Research (MOC), Schlieren, Switzerland
| | | | - Nadine Trost
- Blood Transfusion Service Zürich, Swiss Red Cross (SRC), Department of Molecular Diagnostics & Research (MOC), Schlieren, Switzerland
| | - Kathrin Neuenschwander
- Blood Transfusion Service Zürich, Swiss Red Cross (SRC), Department of Molecular Diagnostics & Research (MOC), Schlieren, Switzerland
| | - Yvonne Merki
- Blood Transfusion Service Zürich, Swiss Red Cross (SRC), Department of Molecular Diagnostics & Research (MOC), Schlieren, Switzerland
| | - Claudia Portmann
- Blood Transfusion Service Zürich, Swiss Red Cross (SRC), Department of Molecular Diagnostics & Research (MOC), Schlieren, Switzerland
| | - Sonja Sigurdardottir
- Blood Transfusion Service Zürich, Swiss Red Cross (SRC), Department of Molecular Diagnostics & Research (MOC), Schlieren, Switzerland
| | - Antigoni Zorbas
- Blood Transfusion Service Zürich, SRC, Schlieren, Switzerland
| | | | | | | | | | - Emmanuel Rigal
- Blood Transfusion Service Genève, SRC, Geneva, Switzerland
| | - Jean-Daniel Tissot
- Blood Transfusion Service Vaud, SRC (recently merged with Interregional Blood Transfusion, SRC, Ltd., Bern), Lausanne, Switzerland
| | | | - Simon M Mauvais
- Blood Transfusion Service Neuchâtel-Jura, SRC, Neuchâtel, Switzerland
| | - Amira Sarraj
- Blood Transfusion Service Neuchâtel-Jura, SRC, Neuchâtel, Switzerland
| | - Daniel Bessero
- Blood Transfusion Service Valais, SRC (recently merged with Interregional Blood Transfusion, SRC, Ltd., Bern), Sion, Switzerland
| | - Michele Stalder
- Blood Transfusion Service Valais, SRC (recently merged with Interregional Blood Transfusion, SRC, Ltd., Bern), Sion, Switzerland
| | - Laura Infanti
- Blood Transfusion Service beider Basel, SRC, Basel, Switzerland
| | - Andreas Buser
- Blood Transfusion Service beider Basel, SRC, Basel, Switzerland
| | - Jörg Sigle
- Blood Transfusion Service Aargau-Solothurn, SRC, Aarau, Switzerland
| | - Tina Weingand
- Blood Transfusion Service Zentralschweiz, SRC, Luzern, Switzerland
| | - Damiano Castelli
- Blood Transfusion Service Svizzera Italiana, SRC, Lugano, Switzerland
| | - Monica C Braisch
- Blood Transfusion Service Ostschweiz, SRC, St. Gallen, Switzerland
| | - Jutta Thierbach
- Blood Transfusion Service Ostschweiz, SRC, St. Gallen, Switzerland
| | - Sonja Heer
- Blood Transfusion Service Graubünden, SRC, Chur, Switzerland
| | - Thomas Schulzki
- Blood Transfusion Service Graubünden, SRC, Chur, Switzerland
| | - Michael Krawczak
- Institute for Medical Informatics and Statistics, Christian-Albrechts-University Kiel, Kiel, Germany
| | - Andre Franke
- Institute of Clinical Molecular Biology, Christian-Albrechts-University of Kiel, Kiel, Germany
| | - Beat M Frey
- Blood Transfusion Service Zürich, SRC, Schlieren, Switzerland
| |
Collapse
|
25
|
Disruption of a GATA1-binding motif upstream of XG/ PBDX abolishes Xg a expression and resolves the Xg blood group system. Blood 2018; 132:334-338. [PMID: 29748255 DOI: 10.1182/blood-2018-03-842542] [Citation(s) in RCA: 22] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/30/2018] [Accepted: 05/07/2018] [Indexed: 12/31/2022] Open
Abstract
The Xga blood group is differentially expressed on erythrocytes from men and women. The underlying gene, PBDX, was identified in 1994, but the molecular background for Xga expression remains undefined. This gene, now designated XG, partly resides in pseudoautosomal region 1 and encodes a protein of unknown function from the X chromosome. By comparing calculated Xga allele frequencies in different populations with 2612 genetic variants in the XG region, rs311103 showed the strongest correlation to the expected distribution. The same single-nucleotide polymorphism (SNP) had the most significant impact on XG transcript levels in whole blood (P = 2.0 × 10-22). The minor allele, rs311103C, disrupts a GATA-binding motif 3.7 kb upstream of the transcription start point. This silences erythroid XG messenger RNA expression and causes the Xg(a-) phenotype, a finding corroborated by SNP genotyping in 158 blood donors. Binding of GATA1 to biotinylated oligonucleotide probes with rs311103G but not rs311103C was observed by electrophoretic mobility shift assay and proven by mass spectrometry. Finally, a luciferase reporter assay indicated this GATA motif to be active for rs311103G but not rs311103C in HEL cells. By using an integrated bioinformatic and molecular biological approach, we elucidated the underlying genetic basis for the last unresolved blood group system and made Xga genotyping possible.
Collapse
|
26
|
Jongruamklang P, Gassner C, Meyer S, Kummasook A, Darlison M, Boonlum C, Chanta S, Frey BM, Olsson ML, Storry JR. Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry analysis of 36 blood group alleles among 396 Thai samples reveals region-specific variants. Transfusion 2018; 58:1752-1762. [PMID: 29656499 DOI: 10.1111/trf.14624] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/27/2017] [Revised: 02/24/2018] [Accepted: 02/26/2018] [Indexed: 12/18/2022]
Abstract
BACKGROUND Blood group phenotype variation has been attributed to potential resistance to pathogen invasion. Variation was mapped in blood donors from Lampang (northern region) and Saraburi (central region), Thailand, where malaria is endemic. The previously unknown blood group allele profiles were characterized and the data were correlated with phenotypes. The high incidence of the Vel-negative phenotype previously reported in Thais was investigated. STUDY DESIGN AND METHODS DNA from 396 blood donors was analyzed by matrix-assisted laser desorption/ionization-time-of-flight mass spectrometry. Outliers were investigated by serology and DNA sequencing. Allele discrimination assays for SMIM1 rs1175550A/G and ACKR1 rs118062001C/T were performed and correlated with antigen expression. RESULTS All samples were phenotyped for Rh, MNS, and K. Genotyping/phenotyping for RhD, K, and S/s showed 100% concordance. Investigation of three RHCE outliers revealed an e-variant antigen encoded by RHCE*02.22. Screening for rs147357308 (RHCE c.667T) revealed a frequency of 3.3%. MN typing discrepancies in 41 samples revealed glycophorin variants, of which 40 of 41 were due to Mia . Nine samples (2.3%) were heterozygous for FY*01W.01 (c.265C > T), and six samples (1.5%) were heterozygous for JK*02N.01. All samples were wildtype SMIM1 homozygotes with 97% homozygosity for rs1175550A. CONCLUSIONS Matrix-assisted laser desorption/ionization-time-of-flight mass spectrometry is an efficient method for rapid routine genotyping and investigation of outliers identified novel variation among our samples. The expected high prevalence of the Mi(a+) phenotype was observed from both regions. Of potential clinical relevance in a region where transfusion-dependent thalassemia is common, we identified two RHCE*02 alleles known to encode an e-variant antigen.
Collapse
Affiliation(s)
- Philaiphon Jongruamklang
- Hematology and Transfusion Medicine, Department of Laboratory Medicine, Lund University, Lund, Sweden
| | - Christoph Gassner
- Molecular Diagnostics & Research (MOC), Blood Transfusion Service Zürich, Zürich-Schlieren, Switzerland
| | - Stefan Meyer
- Molecular Diagnostics & Research (MOC), Blood Transfusion Service Zürich, Zürich-Schlieren, Switzerland
| | - Aksarakorn Kummasook
- Department of Medical Technology, School of Allied Health Sciences, University of Phayao, Phayao, Thailand
| | - Marion Darlison
- Hematology and Transfusion Medicine, Department of Laboratory Medicine, Lund University, Lund, Sweden
| | - Chayanun Boonlum
- Transfusion Medicine, Department of Medical Technology and Clinical Laboratory, Saraburi Hospital, Saraburi, Thailand
| | - Surin Chanta
- Transfusion Medicine, Department of Medical Technology and Clinical Laboratory, Lampang Hospital, Lampang, Thailand
| | - Beat M Frey
- Molecular Diagnostics & Research (MOC), Blood Transfusion Service Zürich, Zürich-Schlieren, Switzerland
| | - Martin L Olsson
- Hematology and Transfusion Medicine, Department of Laboratory Medicine, Lund University, Lund, Sweden.,Clinical Immunology and Transfusion Medicine, Laboratory Medicine, Office of Medical Services, Lund, Sweden
| | - Jill R Storry
- Hematology and Transfusion Medicine, Department of Laboratory Medicine, Lund University, Lund, Sweden.,Clinical Immunology and Transfusion Medicine, Laboratory Medicine, Office of Medical Services, Lund, Sweden
| |
Collapse
|
27
|
Möller M, Hellberg Å, Olsson ML. Thorough analysis of unorthodoxABOdeletions called by the 1000 Genomes project. Vox Sang 2017; 113:185-197. [DOI: 10.1111/vox.12613] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/06/2017] [Revised: 10/23/2017] [Accepted: 10/24/2017] [Indexed: 01/15/2023]
Affiliation(s)
- M. Möller
- Department of Laboratory Medicine, Hematology and Transfusion Medicine; Lund University; Lund Sweden
| | - Å. Hellberg
- Department of Clinical Immunology and Transfusion Medicine; Laboratory Medicine Office of Medical Service; Region Skåne Sweden
| | - M. L. Olsson
- Department of Laboratory Medicine, Hematology and Transfusion Medicine; Lund University; Lund Sweden
- Department of Clinical Immunology and Transfusion Medicine; Laboratory Medicine Office of Medical Service; Region Skåne Sweden
| |
Collapse
|
28
|
Flegel WA, Gottschall JL, Denomme GA. Integration of red cell genotyping into the blood supply chain: a population-based study. LANCET HAEMATOLOGY 2017. [PMID: 26207259 DOI: 10.1016/s2352-3026(15)00090-3] [Citation(s) in RCA: 61] [Impact Index Per Article: 8.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
BACKGROUND When problems with compatibility arise, transfusion services often use time-consuming serological tests to identify antigen-negative red cell units for safe transfusion. New methods have made red cell genotyping possible for all clinically relevant blood group antigens. We did mass-scale genotyping of donor blood and provided hospitals with access to a large red cell database to meet the demand for antigen-negative red cell units beyond ABO and Rh blood typing. METHODS We established a red cell genotype database at the BloodCenter of Wisconsin on July 17, 2010. All self-declared African American, Asian, Hispanic, and Native American blood donors were eligible irrespective of their ABO and Rh type or history of donation. Additionally, blood donors who were groups O, A, and B, irrespective of their Rh phenotype, were eligible for inclusion only if they had a history of at least three donations in the previous 3 years, with one donation in the previous 12 months at the BloodCenter of Wisconsin. We did red cell genotyping with a nanofluidic microarray system, using 32 single nucleotide polymorphisms to predict 42 blood group antigens. An additional 14 antigens were identified via serological phenotype. We monitored the ability of the red cell genotype database to meet demand for compatible blood during 3 years. In addition to the central database at the BloodCenter of Wisconsin, we gave seven hospitals online access to a web-based antigen query portal on May 1, 2013, to help them to locate antigen-negative red cell units in their own inventories. FINDINGS We analysed genotype data for 43,066 blood donors. Requests were filled for 5661 (99.8%) of 5672 patient encounters in which antigen-negative red cell units were needed. Red cell genotyping met the demand for antigen-negative blood in 5339 (94.1%) of 5672 patient encounters, and the remaining 333 (5.9%) requests were filled by use of serological data. Using the 42 antigens represented in our red cell genotype database, we were able to fill 14,357 (94.8%) of 15,140 requests for antigen-negative red cell units from hospitals served by the BloodCenter of Wisconsin. In the pilot phase, the seven hospitals identified 71 units from 52 antigen-negative red cell unit requests. INTERPRETATION Red cell genotyping has the potential to transform the way antigen-negative red cell units are provided. An antigen query portal could reduce the need for transportation of blood and serological screening. If this wealth of genotype data can be made easily accessible online, it will help with the supply of affordable antigen-negative red cell units to ensure patient safety. FUNDING BloodCenter of Wisconsin Diagnostic Laboratories Strategic Initiative and the NIH Clinical Center Intramural Research Program.
Collapse
|
29
|
Affiliation(s)
- A. K. Hult
- Division of Laboratory Medicine; Clinical Immunology and Transfusion Medicine; Office of Medical Services; Lund Sweden
- Division of Hematology and Transfusion Medicine; Department of Laboratory Medicine; Lund University; Lund Sweden
| |
Collapse
|
30
|
Liu TX, Liu YC, Ma L, Zhao F, Zhang RY, Shi LL. Molecular screening of Vel-blood donors using DNA pools in Nanjing, China. Transfus Med 2017; 27:457-459. [PMID: 28881066 DOI: 10.1111/tme.12460] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/20/2017] [Revised: 07/22/2017] [Accepted: 08/10/2017] [Indexed: 11/30/2022]
Affiliation(s)
- T X Liu
- Immunohematology Laboratory, Jiangsu Province Blood Center, Nanjing, China
| | - Y C Liu
- Immunohematology Laboratory, Jiangsu Province Blood Center, Nanjing, China
| | - L Ma
- Immunohematology Laboratory, Jiangsu Province Blood Center, Nanjing, China
| | - F Zhao
- Immunohematology Laboratory, Jiangsu Province Blood Center, Nanjing, China
| | - R Y Zhang
- Immunohematology Laboratory, Jiangsu Province Blood Center, Nanjing, China
| | - L L Shi
- Immunohematology Laboratory, Jiangsu Province Blood Center, Nanjing, China
| |
Collapse
|
31
|
Schoeman EM, Lopez GH, McGowan EC, Millard GM, O'Brien H, Roulis EV, Liew YW, Martin JR, McGrath KA, Powley T, Flower RL, Hyland CA. Evaluation of targeted exome sequencing for 28 protein-based blood group systems, including the homologous gene systems, for blood group genotyping. Transfusion 2017; 57:1078-1088. [PMID: 28338218 DOI: 10.1111/trf.14054] [Citation(s) in RCA: 49] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/08/2016] [Revised: 11/22/2016] [Accepted: 12/02/2016] [Indexed: 01/06/2023]
Abstract
BACKGROUND Blood group single nucleotide polymorphism genotyping probes for a limited range of polymorphisms. This study investigated whether massively parallel sequencing (also known as next-generation sequencing), with a targeted exome strategy, provides an extended blood group genotype and the extent to which massively parallel sequencing correctly genotypes in homologous gene systems, such as RH and MNS. STUDY DESIGN AND METHODS Donor samples (n = 28) that were extensively phenotyped and genotyped using single nucleotide polymorphism typing, were analyzed using the TruSight One Sequencing Panel and MiSeq platform. Genes for 28 protein-based blood group systems, GATA1, and KLF1 were analyzed. Copy number variation analysis was used to characterize complex structural variants in the GYPC and RH systems. RESULTS The average sequencing depth per target region was 66.2 ± 39.8. Each sample harbored on average 43 ± 9 variants, of which 10 ± 3 were used for genotyping. For the 28 samples, massively parallel sequencing variant sequences correctly matched expected sequences based on single nucleotide polymorphism genotyping data. Copy number variation analysis defined the Rh C/c alleles and complex RHD hybrids. Hybrid RHD*D-CE-D variants were correctly identified, but copy number variation analysis did not confidently distinguish between D and CE exon deletion versus rearrangement. CONCLUSION The targeted exome sequencing strategy employed extended the range of blood group genotypes detected compared with single nucleotide polymorphism typing. This single-test format included detection of complex MNS hybrid cases and, with copy number variation analysis, defined RH hybrid genes along with the RHCE*C allele hitherto difficult to resolve by variant detection. The approach is economical compared with whole-genome sequencing and is suitable for a red blood cell reference laboratory setting.
Collapse
Affiliation(s)
| | | | | | | | | | | | - Yew-Wah Liew
- Red Cell Reference Laboratory, Australian Red Cross Blood Service, Brisbane, Queensland, Australia
| | - Jacqueline R Martin
- Red Cell Reference Laboratory, Australian Red Cross Blood Service, Brisbane, Queensland, Australia
| | - Kelli A McGrath
- Red Cell Reference Laboratory, Australian Red Cross Blood Service, Brisbane, Queensland, Australia
| | - Tanya Powley
- Red Cell Reference Laboratory, Australian Red Cross Blood Service, Brisbane, Queensland, Australia
| | | | | |
Collapse
|
32
|
Nam S. Databases and tools for constructing signal transduction networks in cancer. BMB Rep 2017; 50:12-19. [PMID: 27502015 PMCID: PMC5319659 DOI: 10.5483/bmbrep.2017.50.1.135] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/08/2016] [Indexed: 12/22/2022] Open
Abstract
Traditionally, biologists have devoted their careers to studying individual biological entities of their own interest, partly due to lack of available data regarding that entity. Large, high-throughput data, too complex for conventional processing methods (i.e., “big data”), has accumulated in cancer biology, which is freely available in public data repositories. Such challenges urge biologists to inspect their biological entities of interest using novel approaches, firstly including repository data retrieval. Essentially, these revolutionary changes demand new interpretations of huge datasets at a systems-level, by so called “systems biology”. One of the representative applications of systems biology is to generate a biological network from high-throughput big data, providing a global map of molecular events associated with specific phenotype changes. In this review, we introduce the repositories of cancer big data and cutting-edge systems biology tools for network generation, and improved identification of therapeutic targets.
Collapse
Affiliation(s)
- Seungyoon Nam
- Department of Life Sciences, Gachon University, Seongnam 13120; Department of Genome Medicine and Science, College of Medicine, Gachon University; Gachon Institute of Genome Medicine and Science, Gachon University Gil Medical Center, Incheon 21565, Korea
| |
Collapse
|
33
|
Christophersen MK, Jöud M, Ajore R, Vege S, Ljungdahl KW, Westhoff CM, Olsson ML, Storry JR, Nilsson B. SMIM1 variants rs1175550 and rs143702418 independently modulate Vel blood group antigen expression. Sci Rep 2017; 7:40451. [PMID: 28084402 PMCID: PMC5233989 DOI: 10.1038/srep40451] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/14/2016] [Accepted: 12/07/2016] [Indexed: 12/11/2022] Open
Abstract
The Vel blood group antigen is expressed on the red blood cells of most individuals. Recently, we described that homozygosity for inactivating mutations in SMIM1 defines the rare Vel-negative phenotype. Still, Vel-positive individuals show great variability in Vel antigen expression, creating a risk for Vel blood typing errors and transfusion reactions. We fine-mapped the regulatory region located in SMIM1 intron 2 in Swedish blood donors, and observed a strong correlation between expression and rs1175550 as well as with a previously unreported tri-nucleotide insertion (rs143702418; C > CGCA). While the two variants are tightly linked in Caucasians, we separated their effects in African Americans, and found that rs1175550G and to a lesser extent rs143702418C independently increase SMIM1 and Vel antigen expression. Gel shift and luciferase assays indicate that both variants are transcriptionally active, and we identified binding of the transcription factor TAL1 as a potential mediator of the increased expression associated with rs1175550G. Our results provide insight into the regulatory logic of Vel antigen expression, and extend the set of markers for genetic Vel blood group typing.
Collapse
Affiliation(s)
- Mikael K Christophersen
- Division of Hematology and Transfusion Medicine, Department of Laboratory Medicine, Lund University, Lund, Sweden
| | - Magnus Jöud
- Division of Hematology and Transfusion Medicine, Department of Laboratory Medicine, Lund University, Lund, Sweden.,Clinical Immunology and Transfusion Medicine, Laboratory Medicine, Office of Medical Services, Lund, Sweden
| | - Ram Ajore
- Division of Hematology and Transfusion Medicine, Department of Laboratory Medicine, Lund University, Lund, Sweden
| | - Sunitha Vege
- Laboratory of Immunohematology and Genomics, New York Blood Center, New York City, NY, USA
| | - Klara W Ljungdahl
- Division of Hematology and Transfusion Medicine, Department of Laboratory Medicine, Lund University, Lund, Sweden
| | - Connie M Westhoff
- Laboratory of Immunohematology and Genomics, New York Blood Center, New York City, NY, USA
| | - Martin L Olsson
- Division of Hematology and Transfusion Medicine, Department of Laboratory Medicine, Lund University, Lund, Sweden.,Clinical Immunology and Transfusion Medicine, Laboratory Medicine, Office of Medical Services, Lund, Sweden
| | - Jill R Storry
- Division of Hematology and Transfusion Medicine, Department of Laboratory Medicine, Lund University, Lund, Sweden.,Clinical Immunology and Transfusion Medicine, Laboratory Medicine, Office of Medical Services, Lund, Sweden
| | - Björn Nilsson
- Division of Hematology and Transfusion Medicine, Department of Laboratory Medicine, Lund University, Lund, Sweden
| |
Collapse
|
34
|
Erythrogene: a database for in-depth analysis of the extensive variation in 36 blood group systems in the 1000 Genomes Project. Blood Adv 2016; 1:240-249. [PMID: 29296939 DOI: 10.1182/bloodadvances.2016001867] [Citation(s) in RCA: 91] [Impact Index Per Article: 11.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/05/2016] [Accepted: 11/11/2016] [Indexed: 01/22/2023] Open
Abstract
Blood group genotyping has recently developed into a clinical tool to improve compatibility of blood transfusions and management of pregnancies. Next-generation sequencing (NGS) is rapidly moving toward routine practice for patient and donor typing and has the potential to remedy some of the limitations of currently used platforms. However, a large-scale investigation into the blood group genotypes obtained by NGS in a multiethnic cohort is lacking. The 1000 Genomes Project provides information on genome variation among 2504 individuals representing 26 populations worldwide. We extracted their NGS data for all 36 blood group systems to a custom-designed database. In total, 210 412 alleles from 43 blood group-related genes were imported and curated. Matching algorithms were developed to compare them to blood group variants identified to date. Of the 1241 non-synonymous variants identified in the coding regions, 241 are known blood group polymorphisms. Interestingly, 357 of the remaining 1000 variants are predicted to occur on extracellular portions of 31 different blood group-carrying proteins and some may represent undiscovered antigens. Of the alleles analyzed, 1504 were not previously described. The ABO/GBGT1/FUT2/FUT3 and GYPB/GYPC genes showed the highest degree of variation per kilobase coding sequence, and ACKR1 variants had the most skewed distribution across 5 continental superpopulations in the dataset. Results were exported to an online search engine, www.erythrogene.com, which presents data according to the allele nomenclature developed for clinical reporting by the International Society of Blood Transfusion. The established database deepens our knowledge on blood group polymorphism globally and provides a long-sought platform for future research.
Collapse
|
35
|
Storry JR, Castilho L, Chen Q, Daniels G, Denomme G, Flegel WA, Gassner C, de Haas M, Hyland C, Keller M, Lomas-Francis C, Moulds JM, Nogues N, Olsson ML, Peyrard T, van der Schoot CE, Tani Y, Thornton N, Wagner F, Wendel S, Westhoff C, Yahalom V. International society of blood transfusion working party on red cell immunogenetics and terminology: report of the Seoul and London meetings. ACTA ACUST UNITED AC 2016; 11:118-122. [PMID: 29093749 DOI: 10.1111/voxs.12280] [Citation(s) in RCA: 49] [Impact Index Per Article: 6.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
The Working Party has met twice since the last report: in Seoul, South Korea 2014, and in London, UK 2015, both in association with the International Society of Blood Transfusion (ISBT) Congress. As in previous meetings, matters pertaining to blood group antigen nomenclature were discussed. Eleven new blood group antigens were added to seven blood group systems. This brings the current total of blood group antigens recognized by the ISBT to 346, of which 308 are clustered within 36 blood groups systems. The remaining 38 antigens are currently unassigned to a known blood group system.
Collapse
Affiliation(s)
- J R Storry
- Department of Clinical Immunology and Transfusion Medicine, Office for Medical Services, Lund, Sweden
| | - L Castilho
- University of Campinas/Hemocentro, Campinas, Brazil
| | - Q Chen
- Jiangsu Province Blood Center, Nanjing, China
| | - G Daniels
- Bristol Institute for Transfusion Sciences, NHS Blood and Transplant, Bristol, UK
| | - G Denomme
- Blood Center of Wisconsin, Milwaukee, WI, USA
| | - W A Flegel
- Department of Transfusion Medicine, Clinical Center, National Institutes of Health, Bethesda, USA
| | - C Gassner
- Blutspende Zurich, Zurich, Switzerland
| | - M de Haas
- Sanquin Blood Supply Foundation, Amsterdam, The Netherlands
| | - C Hyland
- Australian Red Cross Blood Services, Brisbane, Qld, Australia
| | - M Keller
- American Red Cross Blood Services, Philadelphia, PA, USA
| | | | | | - N Nogues
- Banc de Sang i Teixits, Barcelona, Spain
| | - M L Olsson
- Department of Laboratory Medicine, Division of Hematology and Transfusion Medicine, Lund University, Lund, Sweden
| | - T Peyrard
- Institut National de la Transfusion Sanguine, Département Centre National de Référence pour les Groupes Sanguins, Inserm UMR_S1134, Paris, France
| | | | - Y Tani
- Osaka Red Cross Blood Center, Osaka, Japan
| | - N Thornton
- International Blood Group Reference Laboratory, NHS Blood and Transplant, Bristol, UK
| | - F Wagner
- Red Cross Blood Service NSTOB, Springe, Germany
| | - S Wendel
- Blood Bank, Hospital Sirio-Libanes, São Paulo, Brazil
| | - C Westhoff
- New York Blood Center, New York, NY, USA
| | - V Yahalom
- NBGRL Magen David Adom, Ramat Gan, Israel
| |
Collapse
|
36
|
Costa DC, Dezan M, Santos T, Schinaider AA, Schörner EJ, Levi JE, Santos-Silva MC. Screening for the SMIM1*64_80 del Allele in blood donors in a population from Southern Brazil. Transfus Med 2016; 26:355-359. [PMID: 27328373 DOI: 10.1111/tme.12328] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/07/2016] [Revised: 05/26/2016] [Accepted: 05/31/2016] [Indexed: 11/28/2022]
Abstract
BACKGROUND AND OBJECTIVES Serological screening for the Vel- phenotype is complex given the large individual variation in the levels of expression of the Vel antigen, and the polyclonal anti-human sera of immunised persons, when available, show heterogeneous reactivity levels. Studies of the SMIM1 gene have enabled the development of several molecular methodologies that will be crucially important for the screening of different populations, including Brazilians. To evaluate the deletion of 17 bp in the SMIM1 gene in a population from the south of Brazil, 448 unrelated blood donors from 7 regions comprising the haemotherapy network in the state of Santa Catarina were evaluated between August 2011 and March 2014. MATERIALS AND METHODS DNA samples from these donors were analysed employing a 5' nuclease real-time polymerase chain reaction (PCR) assay targeting the 17 bp deletion in the SMIM1 gene. RESULTS Among the 448 samples analysed, 10 (2·23%) harboured the 17 bp deletion of the gene SMIM1, and all were heterozygote for the SMIM1*64_80 del allele. CONCLUSION The allelic frequency found differed from those observed in other Caucasian populations. This difference can be explained by the ethnic make-up of each Caucasian population. The data obtained are important to characterise the correct phenotype of the donor as the serological assay results are not reliable due to variations in the expression intensity of the Vel antigen in heterozygote donors for the SMIM1*64_80 del allele. Moreover, the tool used in this study is of great value for identifying a donor Vel- phenotype and supplying a possible need for transfusion.
Collapse
Affiliation(s)
- D C Costa
- Graduate Program in Pharmacy, Federal University of Santa Catarina, UFSC, Florianópolis, Brazil
| | - M Dezan
- Fundação Pró-Sangue/Hemocentro de São Paulo, Rua Dr. Enéas Carvalho Aguiar, São Paulo, Brazil
| | - T Santos
- Department of Clinical Analyses, Federal University of Santa Catarina, UFSC, Florianópolis, Brazil
| | - A A Schinaider
- Department of Clinical Analyses, Federal University of Santa Catarina, UFSC, Florianópolis, Brazil
| | - E J Schörner
- Immunohematology Laboratory, Santa Catarina Blood Bank, HEMOSC, Avenida Professor Othon Gama D'Eça, Florianópolis, Brazil
| | - J E Levi
- Fundação Pró-Sangue/Hemocentro de São Paulo, Rua Dr. Enéas Carvalho Aguiar, São Paulo, Brazil
| | - M C Santos-Silva
- Department of Clinical Analyses, Federal University of Santa Catarina, UFSC, Florianópolis, Brazil.
| |
Collapse
|
37
|
Dezan MR, Dinardo CL, Bosi SRA, Vega S, Salles NA, Mendrone-Júnior A, Levi JE. High-throughput strategy for molecular identification of Vel- blood donors employing nucleic acids extracted from plasma pools used for viral nucleic acid test screening. Transfusion 2016; 56:1430-4. [PMID: 27060345 DOI: 10.1111/trf.13572] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/17/2015] [Revised: 01/11/2016] [Accepted: 01/21/2016] [Indexed: 11/28/2022]
Abstract
BACKGROUND Serologic methods to determine the Vel- phenotype require the use of rare human antisera and do not allow for many samples to be tested simultaneously, which limits their application as a tool to search for rare donors. This study developed a low-cost molecular screening strategy using real-time polymerase chain reaction (PCR) and DNA, extracted from plasma pools for viral nucleic acid test (NAT) screening, to identify Vel- and Vel+(W) donors. STUDY DESIGN AND METHODS A total of 4680 blood donors from the Brazilian southeast region were genotyped through real-time PCR targeting the 17-nucleotide (c.64_80del) deletion in the SMIM1 gene, which determines the Vel- phenotype, by using remaining nucleic acid from plasma pools of six donors, routinely discarded after the release of viral NAT results. RESULTS Twenty pools tested reactive and individual testing of samples from reactive pools identified 19 heterozygous donors with the SMIM1*64_80del deletion (0.40%) and one homozygous donor (0.02%). Fourteen of the 19 donors were confirmed as Vel- or Vel+(W) using anti-Vel human antiserum. CONCLUSION The DNA pool genotyping strategy using real-time PCR designed to detect the deletion in the SMIM1 gene proved effective and accurate in identifying donors with the Vel- and Vel+(W) phenotypes. The fact that remaining nucleic acid from routine viral NAT screening was used makes this technique economically attractive and definitely superior to the serologic techniques available to search for this rare phenotype.
Collapse
Affiliation(s)
- Marcia R Dezan
- Fundação Pró-Sangue/Hemocentro de São Paulo, São Paulo, Brazil
| | - Carla L Dinardo
- Fundação Pró-Sangue/Hemocentro de São Paulo, São Paulo, Brazil
| | - Silvia R A Bosi
- Fundação Pró-Sangue/Hemocentro de São Paulo, São Paulo, Brazil
| | - Sileni Vega
- Fundação Pró-Sangue/Hemocentro de São Paulo, São Paulo, Brazil
| | - Nanci A Salles
- Fundação Pró-Sangue/Hemocentro de São Paulo, São Paulo, Brazil
| | | | - José E Levi
- Fundação Pró-Sangue/Hemocentro de São Paulo, São Paulo, Brazil
| |
Collapse
|
38
|
Satchwell TJ. Erythrocyte invasion receptors for Plasmodium falciparum: new and old. Transfus Med 2016; 26:77-88. [PMID: 26862042 DOI: 10.1111/tme.12280] [Citation(s) in RCA: 28] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/28/2015] [Revised: 12/18/2015] [Accepted: 01/11/2016] [Indexed: 12/20/2022]
Abstract
Understanding the complex process by which the invasive form of the Plasmodium falciparum parasite, the merozoite, attaches to and invades erythrocytes as part of its blood stage life cycle represents a key area of research in the battle to combat malaria. Central to this are efforts to determine the identity of receptors on the host cell surface, their corresponding merozoite-binding proteins and the functional relevance of these binding events as part of the invasion process. This review will provide an updated summary of studies identifying receptor interactions essential for or implicated in P. falciparum merozoite invasion of human erythrocytes, highlighting the recent identification of new receptors using groundbreaking high throughput approaches and with particular focus on the properties and putative involvement of the erythrocyte proteins targeted by these invasion pathways.
Collapse
Affiliation(s)
- T J Satchwell
- School of Biochemistry, Biomedical Sciences Building, University Walk, Bristol, UK
| |
Collapse
|
39
|
Nance S, Scharberg EA, Thornton N, Yahalom V, Sareneva I, Lomas-Francis C. International rare donor panels: a review. Vox Sang 2015; 110:209-18. [DOI: 10.1111/vox.12357] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/16/2015] [Revised: 08/11/2015] [Accepted: 09/20/2015] [Indexed: 12/27/2022]
Affiliation(s)
- S. Nance
- IRL; Biomedical Services; American Red Cross; Philadelphia PA USA
| | - E. A. Scharberg
- Institute for Transfusion Medicine and Immunohematology; Red Cross Transfusion Service of Baden-Wuerttemberg-Hessen gGmbH; Baden-Baden Germany
| | - N. Thornton
- The International Blood Group Reference Laboratory; NHS Blood and Transplant; Filton Bristol UK
| | - V. Yahalom
- National Blood Services; Ramat Gan Israel
| | - I. Sareneva
- Blood Group Unit; Finnish Red Cross Blood Service; Helsinki Finland
| | - C. Lomas-Francis
- New York Blood Center; Laboratory of Immunohematology and Genomics; Long Island City NY USA
| |
Collapse
|
40
|
Coghlan G, Zelinski T. The c.64_80del SMIM1 allele is segregating in the Hutterite population. Transfusion 2015; 56:946-9. [PMID: 26666208 DOI: 10.1111/trf.13439] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/21/2015] [Revised: 10/09/2015] [Accepted: 11/02/2015] [Indexed: 11/29/2022]
Abstract
BACKGROUND The high-incidence red blood cell (RBC) antigen Vel is coded by SMIM1 (small-membrane molecule 1 gene), where a homozygous 17 base pair deletion underlies the majority of Vel- phenotypes. Because anti-Vel has been reported to cause severe hemolytic transfusion reactions and periodically hemolytic disease of the newborn and fetus, identification of individuals negative for Vel is clinically important. STUDY DESIGN AND METHODS RBCs from the members of a large three-generation Hutterite family were serologically determined to be Vel+(w) . Genomic DNA from these family members was polymerase chain reaction amplified and analyzed for SMIM1 polymorphisms by either Sanger sequencing or restriction fragment length polymorphisms. SMIM1 genotyping was also conducted on DNA from an additional 104 Hutterites. RESULTS All family members whose RBCs weakly expressed the Vel antigen were found to be heterozygous for the c.64_80del mutation in SMIM1. Of the 104 additional Hutterite samples, four were found to be heterozygous for the same SMIM1 mutation. CONCLUSION After emigrating to the United States and Canada, the Hutterite population has expanded dramatically. Alleles that initially entered the population have been maintained within the population. The c.64_80del null allele of SMIM1 is one such allele, thus having implications for transfusion medicine and child or maternal health.
Collapse
Affiliation(s)
- Gail Coghlan
- Rh Laboratory, Department of Pediatrics and Child Health, University of Manitoba, Winnipeg, Manitoba, Canada
| | - Teresa Zelinski
- Rh Laboratory, Department of Pediatrics and Child Health, University of Manitoba, Winnipeg, Manitoba, Canada.,Department of Biochemistry and Medical Genetics, Faculty of Health Sciences, College of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada
| |
Collapse
|
41
|
Lane WJ, Westhoff CM, Uy JM, Aguad M, Smeland-Wagman R, Kaufman RM, Rehm HL, Green RC, Silberstein LE. Comprehensive red blood cell and platelet antigen prediction from whole genome sequencing: proof of principle. Transfusion 2015; 56:743-54. [PMID: 26634332 PMCID: PMC5019240 DOI: 10.1111/trf.13416] [Citation(s) in RCA: 67] [Impact Index Per Article: 7.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/27/2015] [Revised: 09/15/2015] [Accepted: 10/14/2015] [Indexed: 12/29/2022]
Abstract
BACKGROUND There are 346 serologically defined red blood cell (RBC) antigens and 33 serologically defined platelet (PLT) antigens, most of which have known genetic changes in 45 RBC or six PLT genes that correlate with antigen expression. Polymorphic sites associated with antigen expression in the primary literature and reference databases are annotated according to nucleotide positions in cDNA. This makes antigen prediction from next-generation sequencing data challenging, since it uses genomic coordinates. STUDY DESIGN AND METHODS The conventional cDNA reference sequences for all known RBC and PLT genes that correlate with antigen expression were aligned to the human reference genome. The alignments allowed conversion of conventional cDNA nucleotide positions to the corresponding genomic coordinates. RBC and PLT antigen prediction was then performed using the human reference genome and whole genome sequencing (WGS) data with serologic confirmation. RESULTS Some major differences and alignment issues were found when attempting to convert the conventional cDNA to human reference genome sequences for the following genes: ABO, A4GALT, RHD, RHCE, FUT3, ACKR1 (previously DARC), ACHE, FUT2, CR1, GCNT2, and RHAG. However, it was possible to create usable alignments, which facilitated the prediction of all RBC and PLT antigens with a known molecular basis from WGS data. Traditional serologic typing for 18 RBC antigens were in agreement with the WGS-based antigen predictions, providing proof of principle for this approach. CONCLUSION Detailed mapping of conventional cDNA annotated RBC and PLT alleles can enable accurate prediction of RBC and PLT antigens from whole genomic sequencing data.
Collapse
Affiliation(s)
- William J Lane
- Department of Pathology.,Harvard Medical School, Boston, Massachusetts
| | | | | | | | | | | | - Heidi L Rehm
- Department of Pathology.,Harvard Medical School, Boston, Massachusetts.,Laboratory for Molecular Medicine.,Partners Healthcare Personalized Medicine, Boston, Massachusetts
| | - Robert C Green
- Division of Genetics, Department of Medicine.,Harvard Medical School, Boston, Massachusetts.,Partners Healthcare Personalized Medicine, Boston, Massachusetts
| | - Leslie E Silberstein
- Division of Transfusion Medicine, Department of Pathology, Brigham and Women's Hospital
| | | |
Collapse
|
42
|
Wieckhusen C, Rink G, Scharberg EA, Rothenberger S, Kömürcü N, Bugert P. Molecular Screening for Vel- Blood Donors in Southwestern Germany. Transfus Med Hemother 2015; 42:356-60. [PMID: 26732700 DOI: 10.1159/000440791] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/18/2015] [Accepted: 05/31/2015] [Indexed: 11/19/2022] Open
Abstract
BACKGROUND The SMIM1 protein carries the Vel blood group antigen, and homozygosity for a 17 bp deletion in the coding region of the SMIM1 gene represents the molecular basis of the Vel- blood group phenotype. We developed PCR-based methods for typing the SMIM1 17 bp (64-80del) gene deletion and performed a molecular screening for the Vel- blood type in German blood donors. METHODS For SMIM1 genotyping, TaqMan-PCR and PCR-SSP methods were developed and validated using reference samples. Both methods were used for screening of donors with blood group O from southwestern Germany. Heterozygotes and homozygotes for the SMIM1 64-80del allele were serologically typed for the Vel blood group antigen. In addition, the rs1175550 SNP in SMIM1 was typed and correlated to the results of the phenotyping. RESULTS Both genotyping methods, TaqMan-PCR and PCR-SSP, represent reliable methods for the detection of the SMIM1 64-80del allele. Screening of 10,598 blood group O donors revealed 5 individuals homozygous for the deletional allele. They were confirmed Vel- by serological typing. Heterozygotes for the 64-80del allele showed different antigen expressions ranging from very weak to regular positive. CONCLUSION Molecular screening of blood donors for the Vel- blood type is feasible and avoids the limitations of serological typing which might show false-negative results with heterozygous individuals. The identification of Vel- blood donors significantly contributes to the adequate blood supply of patients with anti-Vel.
Collapse
Affiliation(s)
- Carola Wieckhusen
- Institute of Transfusion Medicine and Immunology, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany
| | - Gabi Rink
- Institute of Transfusion Medicine and Immunology, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany
| | - Erwin A Scharberg
- Institute of Transfusion Medicine and Immunohematology, Baden-Baden; German Red Cross Blood Service Baden-Württemberg - Hessen, Baden-Baden, Germany
| | - Sina Rothenberger
- Institute of Transfusion Medicine and Immunohematology, Baden-Baden; German Red Cross Blood Service Baden-Württemberg - Hessen, Baden-Baden, Germany
| | - Naime Kömürcü
- Institute of Transfusion Medicine and Immunohematology, Baden-Baden; German Red Cross Blood Service Baden-Württemberg - Hessen, Baden-Baden, Germany
| | - Peter Bugert
- Institute of Transfusion Medicine and Immunology, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany
| |
Collapse
|
43
|
SMIM1 is a type II transmembrane phosphoprotein and displays the Vel blood group antigen at its carboxyl-terminus. FEBS Lett 2015; 589:3624-30. [PMID: 26452714 DOI: 10.1016/j.febslet.2015.09.029] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/12/2015] [Revised: 09/03/2015] [Accepted: 09/23/2015] [Indexed: 11/22/2022]
Abstract
Disruption of SMIM1, encoding small integral membrane protein 1, is responsible for the Vel-negative blood type, a rare but clinically-important blood type. However, the exact nature of the Vel antigen and how it is presented by SMIM1 are poorly understood. Using mass spectrometry we found several sites of phosphorylation in the N-terminal region of SMIM1 and we found the initiating methionine of SMIM1 to be acetylated. Flow cytometry analyses of human erythroleukemia cells expressing N- or C-terminally Flag-tagged SMIM1, several point mutants of SMIM1, and a chimeric molecule between Kell and SMIM1 demonstrated that SMIM1 carries the Vel antigen as a type II membrane protein with a predicted C-terminal extracellular domain of only 3-12 amino acids.
Collapse
|
44
|
Danger Y, Danard S, Gringoire V, Peyrard T, Riou P, Semana G, Vérité F. Characterization of a new human monoclonal antibody directed against the Vel antigen. Vox Sang 2015; 110:172-8. [PMID: 26382919 DOI: 10.1111/vox.12321] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/10/2015] [Revised: 06/01/2015] [Accepted: 07/11/2015] [Indexed: 12/01/2022]
Abstract
BACKGROUND AND OBJECTIVES The Vel blood group antigen is a poorly characterized high-prevalence antigen. Until now, anti-Vel antibodies have been observed in only alloimmunized Vel-negative individuals. In this study, we aimed to establish a human hybridoma cell line secreting the first anti-Vel monoclonal antibody (mAb), clone SpG213Dc. MATERIALS AND METHODS Peripheral blood lymphocytes from a French Vel-negative woman with anti-Vel in her plasma were transformed with Epstein-Barr virus and then hybridized with the myeloma cell line Sp2/O-Ag14 using the polyethylene glycol (PEG) method. A specific anti-Vel mAb was successfully produced and was extensively characterized by serological, flow cytometry and Western blot analyses. RESULTS One human anti-Vel-secreting clone was produced and the secreted anti-Vel mAb (SpG213Dc) was examined. The specificity of the SpG213Dc mAb was assessed by its reactivity against a panel of nine genotyped RBCs including, respectively, three Vel-negative and six Vel-positive (three wild-type homozygous and three heterozygous) samples using flow cytometry method. Vel-positive RBCs were specifically stained and were subsequently used to perform Western blot and immunoprecipitation analysis of the Vel antigen. CONCLUSION Serological characterization of the new monoclonal anti-Vel SpG213Dc showed a heterogeneous level of expression of the Vel antigen on the different RBCs. Our results suggest that the mAb SpG213Dc can be reliably used as a blood grouping reagent, thus allowing the mass-scale phenotyping of blood donors to strengthen rare blood banks with Vel-negative RBC units.
Collapse
Affiliation(s)
- Y Danger
- EFS Bretagne, Rennes, France.,Structure Fédérative BioSit UMS 3480 CNRS-US18 Inserm, Rennes, France
| | | | | | - T Peyrard
- Institut National de la Transfusion Sanguine, Département Centre National de Référence pour les Groupes Sanguins, Paris, France.,INSERM UMR_S1134, Paris, France.,Laboratoire d'Excellence LABEX GR-Ex, Paris, France
| | - P Riou
- EFS Bretagne, Rennes, France
| | | | - F Vérité
- EFS Bretagne, Rennes, France.,Structure Fédérative BioSit UMS 3480 CNRS-US18 Inserm, Rennes, France
| |
Collapse
|
45
|
Villa CH, Pan DC, Zaitsev S, Cines DB, Siegel DL, Muzykantov VR. Delivery of drugs bound to erythrocytes: new avenues for an old intravascular carrier. Ther Deliv 2015; 6:795-826. [PMID: 26228773 PMCID: PMC4712023 DOI: 10.4155/tde.15.34] [Citation(s) in RCA: 79] [Impact Index Per Article: 8.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022] Open
Abstract
For several decades, researchers have used erythrocytes for drug delivery of a wide variety of therapeutics in order to improve their pharmacokinetics, biodistribution, controlled release and pharmacodynamics. Approaches include encapsulation of drugs within erythrocytes, as well as coupling of drugs onto the red cell surface. This review focuses on the latter approach, and examines the delivery of red blood cell (RBC)-surface-bound anti-inflammatory, anti-thrombotic and anti-microbial agents, as well as RBC carriage of nanoparticles. Herein, we discuss the progress that has been made in surface loading approaches, and address in depth the issues relevant to surface loading of RBC, including intrinsic features of erythrocyte membranes, immune considerations, potential surface targets and techniques for the production of affinity ligands.
Collapse
Affiliation(s)
- Carlos H Villa
- Department of Pathology & Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA
| | - Daniel C Pan
- Department of Systems Pharmacology & Translational Therapeutics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA
| | - Sergei Zaitsev
- Department of Systems Pharmacology & Translational Therapeutics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA
| | - Douglas B Cines
- Department of Pathology & Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA
| | - Donald L Siegel
- Department of Pathology & Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA
| | - Vladimir R Muzykantov
- Department of Systems Pharmacology & Translational Therapeutics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA
| |
Collapse
|
46
|
Haer-Wigman L, Stegmann TC, Solati S, Ait Soussan A, Beckers E, van der Harst P, van Hulst-Sundermeijer M, Ligthart P, van Rhenen D, Schepers H, de Haas M, van der Schoot CE. Impact of genetic variation in the SMIM1 gene on Vel expression levels. Transfusion 2015; 55:1457-66. [PMID: 25647324 DOI: 10.1111/trf.13014] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/31/2014] [Revised: 10/07/2014] [Accepted: 10/21/2014] [Indexed: 01/12/2023]
Abstract
BACKGROUND Serologic determination of the Vel- phenotype is challenging due to variable Vel expression levels. In this study we investigated the genetic basis for weak Vel expression levels and developed a high-throughput genotyping assay to detect Vel- donors. STUDY DESIGN AND METHODS In 548 random Caucasian and 107 Vel+(w) donors genetic variation in the SMIM1 gene was studied and correlated to Vel expression levels. A total of 3366 Caucasian, 621 black, and 333 Chinese donors were screened with a high-throughput genotyping assay targeting the SMIM1*64_80del allele. RESULTS The Vel+(w) phenotype is in most cases caused by the presence of one SMIM1 allele carrying the major allele of the rs1175550 SNP in combination with a SMIM1*64_80del allele or in few cases caused by the presence of the SMIM1*152T>A or SMIM1*152T>G allele. In approximately 6% of Vel+(w) donors genetic factors in SMIM1 could not explain the weak expression. We excluded the possibility that lack of expression of another blood group system was correlated with weak Vel expression levels. Furthermore, using a high-throughput Vel genotyping assay we detected two Caucasian Vel- donors. CONCLUSION Weak Vel expression levels are caused by multiple genetic factors in SMIM1 and probably also by other genetic or environmental factors. Due to the variation in Vel expression levels, serologic determination of the Vel- phenotype is difficult and a genotyping assay targeting the c.64_80del deletion in SMIM1 should be used to screen donors for the Vel- phenotype.
Collapse
Affiliation(s)
- Lonneke Haer-Wigman
- Sanquin Research, Amsterdam and Landsteiner Laboratory, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands
| | - Tamara C Stegmann
- Sanquin Research, Amsterdam and Landsteiner Laboratory, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands
| | - Shabnam Solati
- Sanquin Research, Amsterdam and Landsteiner Laboratory, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands
| | - Aïcha Ait Soussan
- Sanquin Research, Amsterdam and Landsteiner Laboratory, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands
| | - Erik Beckers
- Maastricht University Medical Center, Maastricht, the Netherlands
| | | | - Marga van Hulst-Sundermeijer
- Department of Stem Cell Biology & Department of Experimental Hematology, Sanquin Diagnostic Services, Amsterdam, the Netherlands
| | - Peter Ligthart
- Sanquin Research, Amsterdam and Landsteiner Laboratory, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands
| | | | - Hein Schepers
- University Medical Center Groningen, University of Groningen, Groningen, the Netherlands
| | - Masja de Haas
- Sanquin Research, Amsterdam and Landsteiner Laboratory, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands
| | - C Ellen van der Schoot
- Sanquin Research, Amsterdam and Landsteiner Laboratory, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands
| |
Collapse
|
47
|
McBean RS, Hyland CA, Hendry JL, Shabani-Rad MT, Flower RL. SARA: a "new" low-frequency MNS antigen (MNS47) provides further evidence of the extreme diversity of the MNS blood group system. Transfusion 2014; 55:1451-6. [PMID: 25523184 DOI: 10.1111/trf.12973] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/07/2014] [Revised: 10/07/2014] [Accepted: 10/12/2014] [Indexed: 11/28/2022]
Abstract
BACKGROUND Until recently, SARAH (SARA) was a low-frequency antigen within the 700 series (700.052). SARA was discovered in Australia and subsequently described in Canada where anti-SARA was implicated in severe hemolytic disease of the fetus and newborn (HDFN). This study investigated whether SARA could be recategorized into an existing, or novel, blood group system. STUDY DESIGN AND METHODS Serologically typed Australian SARA family members (n = 9) were exome sequenced followed by bioinformatics analysis. Sanger sequencing of Exon 3 of GYPA of Australian (n = 9) and Canadian (n = 9) family members was then performed, as were peptide inhibition studies. RESULTS Exome sequencing identified 499,329 single-nucleotide variants (SNVs) within the nine individuals. Filtering excluded SNVs with an NCBI dbSNP ID (n = 482,177) and non-protein coding SNVs (n = 14,008); for the remaining 3144 SNVs, only one, c.240G>T of GYPA encoding p.Arg80Ser, was present in all six SARA-positive individuals. Sanger sequencing confirmed the presence of c.240G>T in the Australian SARA-positive individuals and demonstrated the same genetic basis in the Canadian SARA family. For a peptide representing the SARA sequence, inhibition of anti-SARA against SARA-positive cells was 84.6% at a concentration of 1.0 mg/mL. CONCLUSION We provide evidence that the SARA antigen is encoded by a SNV on GYPA and SARA has been reassigned to the MNS blood group system, now MNS47. This discovery provides a basis for application of genetic approaches in SARA typing when clinically indicated, for example, in HDFN.
Collapse
Affiliation(s)
- Rhiannon S McBean
- Research and Development, Australian Red Cross Blood Service, Kelvin Grove, Queensland, Australia
| | - Catherine A Hyland
- Research and Development, Australian Red Cross Blood Service, Kelvin Grove, Queensland, Australia
| | - Julia L Hendry
- Transfusion Medicine, Calgary Laboratory Services, Calgary, Alberta, Canada
| | | | - Robert L Flower
- Research and Development, Australian Red Cross Blood Service, Kelvin Grove, Queensland, Australia
| |
Collapse
|
48
|
Liu Z, Liu M, Mercado T, Illoh O, Davey R. Extended blood group molecular typing and next-generation sequencing. Transfus Med Rev 2014; 28:177-86. [PMID: 25280589 DOI: 10.1016/j.tmrv.2014.08.003] [Citation(s) in RCA: 28] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/28/2014] [Revised: 08/11/2014] [Accepted: 08/25/2014] [Indexed: 02/09/2023]
Abstract
Several high-throughput multiplex blood group molecular typing platforms have been developed to predict blood group antigen phenotypes. These molecular systems support extended donor/patient matching by detecting commonly encountered blood group polymorphisms as well as rare alleles that determine the expression of blood group antigens. Extended molecular typing of a large number of blood donors by high-throughput platforms can increase the likelihood of identifying donor red blood cells that match those of recipients. This is especially important in the management of multiply-transfused patients who may have developed several alloantibodies. Nevertheless, current molecular techniques have limitations. For example, they detect only predefined genetic variants. In contrast, target enrichment next-generation sequencing (NGS) is an emerging technology that provides comprehensive sequence information, focusing on specified genomic regions. Target enrichment NGS is able to assess genetic variations that cannot be achieved by traditional Sanger sequencing or other genotyping platforms. Target enrichment NGS has been used to detect both known and de novo genetic polymorphisms, including single-nucleotide polymorphisms, indels (insertions/deletions), and structural variations. This review discusses the methodology, advantages, and limitations of the current blood group genotyping techniques and describes various target enrichment NGS approaches that can be used to develop an extended blood group genotyping assay system.
Collapse
Affiliation(s)
- Zhugong Liu
- Division of Blood Components and Devices, Office of Blood Research and Review, Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, MD.
| | - Meihong Liu
- Division of Blood Components and Devices, Office of Blood Research and Review, Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, MD
| | - Teresita Mercado
- Division of Blood Components and Devices, Office of Blood Research and Review, Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, MD
| | - Orieji Illoh
- Division of Blood Components and Devices, Office of Blood Research and Review, Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, MD
| | - Richard Davey
- Division of Blood Components and Devices, Office of Blood Research and Review, Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, MD
| |
Collapse
|
49
|
Morales M, Ávila J, González-Fernández R, Boronat L, Soriano ML, Martín-Vasallo P. Differential transcriptome profile of peripheral white cells to identify biomarkers involved in oxaliplatin induced neuropathy. J Pers Med 2014; 4:282-96. [PMID: 25563226 PMCID: PMC4263976 DOI: 10.3390/jpm4020282] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/25/2014] [Revised: 05/21/2014] [Accepted: 05/28/2014] [Indexed: 12/26/2022] Open
Abstract
Anticancer chemotherapy (CT) produces non-desirable effects on normal healthy cells and tissues. Oxaliplatin is widely used in the treatment of colorectal cancer and responsible for the development of sensory neuropathy in varying degrees, from complete tolerance to chronic neuropathic symptoms. We studied the differential gene expression of peripheral leukocytes in patients receiving oxaliplatin-based chemotherapy to find genes and pathways involved in oxaliplatin-induced peripheral neuropathy. Circulating white cells were obtained prior and after three cycles of FOLFOX or CAPOX chemotherapy from two groups of patients: with or without neuropathy. RNA was purified, and transcriptomes were analyzed. Differential transcriptomics revealed a total of 502 genes, which were significantly up- or down-regulated as a result of chemotherapy treatment. Nine of those genes were expressed in only one of two situations: CSHL1, GH1, KCMF1, IL36G and EFCAB8 turned off after CT, and CSRP2, IQGAP1, GNRH2, SMIM1 and C5orf17 turned on after CT. These genes are likely to be associated with the onset of oxaliplatin-induced peripheral neuropathy. The quantification of their expression in peripheral white cells may help to predict non-desirable side effects and, consequently, allow a better, more personalized chemotherapy.
Collapse
Affiliation(s)
- Manuel Morales
- Service of Oncology, Hospital Universitario Nuestra Señora de Candelaria, Santa Cruz de Tenerife, 38010 Tenerife, Spain.
| | - Julio Ávila
- Developmental Biology Laboratory, Department of Biochemistry and Molecular Biology, University of La Laguna, Av. Astrofísico Sánchez s/n, 38206 La Laguna, Spain.
| | - Rebeca González-Fernández
- Developmental Biology Laboratory, Department of Biochemistry and Molecular Biology, University of La Laguna, Av. Astrofísico Sánchez s/n, 38206 La Laguna, Spain.
| | - Laia Boronat
- Service of Oncology, Hospital Universitario Nuestra Señora de Candelaria, Santa Cruz de Tenerife, 38010 Tenerife, Spain.
| | - María Luisa Soriano
- Service of Oncology, Hospital Universitario Nuestra Señora de Candelaria, Santa Cruz de Tenerife, 38010 Tenerife, Spain.
| | - Pablo Martín-Vasallo
- Developmental Biology Laboratory, Department of Biochemistry and Molecular Biology, University of La Laguna, Av. Astrofísico Sánchez s/n, 38206 La Laguna, Spain.
| |
Collapse
|
50
|
Meyer S, Vollmert C, Trost N, Brönnimann C, Gottschalk J, Buser A, Frey BM, Gassner C. High-throughput Kell, Kidd, and Duffy matrix-assisted laser desorption/ionization, time-of-flight mass spectrometry-based blood group genotyping of 4000 donors shows close to full concordance with serotyping and detects new alleles. Transfusion 2014; 54:3198-207. [DOI: 10.1111/trf.12715] [Citation(s) in RCA: 37] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/09/2013] [Revised: 03/05/2014] [Accepted: 04/06/2014] [Indexed: 11/26/2022]
Affiliation(s)
- Stefan Meyer
- Department of Molecular Diagnostics & Cytometry (MOC); Swiss Red Cross; Schlieren Switzerland
| | | | - Nadine Trost
- Department of Molecular Diagnostics & Cytometry (MOC); Swiss Red Cross; Schlieren Switzerland
| | - Chantal Brönnimann
- Department of Molecular Diagnostics & Cytometry (MOC); Swiss Red Cross; Schlieren Switzerland
| | - Jochen Gottschalk
- Blood Transfusion Service Zurich; Swiss Red Cross; Schlieren Switzerland
| | - Andreas Buser
- Blood Transfusion Center Basel; Swiss Red Cross; Basel Switzerland
| | - Beat M. Frey
- Blood Transfusion Service Zurich; Swiss Red Cross; Schlieren Switzerland
| | - Christoph Gassner
- Department of Molecular Diagnostics & Cytometry (MOC); Swiss Red Cross; Schlieren Switzerland
| |
Collapse
|